Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient

array:24 ["pii" => "S1578219018302324" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.020" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "1954" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2018;109:584-601" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6 "formatos" => array:2 [ "HTML" => 1 "PDF" => 5 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731018301790" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.03.013" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "1954" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2018;109:584-601" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1057 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 732 "PDF" => 324 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "ARTÍCULO ESPECIAL" "titulo" => "Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "584" "paginaFinal" => "601" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2665 "Ancho" => 2167 "Tamanyo" => 302244 ] ] "descripcion" => array:1 [ "es" => "En ausencia de anti-FNT-α, las células T citotóxicas efectoras de memoria (TEMRA) liberan los gránulos con enzimas citolíticas (perforina, granulolisina) que destruyen los macrófagos infectados por M. tuberculosis así como los bacilos intra- y extracelulares. En presencia de anti-FNT-α, el FNT transmembrana de los TEMRA queda ligado a este anticuerpo, favoreciendo la apoptosis linfocitaria. La depleción de linfocitos T citotóxicos impide, por tanto, el control del crecimiento y permite la diseminación de M. tuberculosis. Fuente: Adaptado de Miller y Ernst.<a class="elsevierStyleCrossRef" href="#bib0805">41</a>." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Rodríguez-Jiménez, I. Mir-Viladrich, P. Chicharro, G. Solano-López, F.J. López-Longo, C. Taxonera, P. Sánchez-Martínez, X. Martínez-Lacasa, M. García-Gasalla, J. Dorca, M. Arias-Guillén, J.M. García-García, E. Dauden" "autores" => array:13 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Rodríguez-Jiménez" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Mir-Viladrich" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Chicharro" ] 3 => array:2 [ "nombre" => "G." "apellidos" => "Solano-López" ] 4 => array:2 [ "nombre" => "F.J." "apellidos" => "López-Longo" ] 5 => array:2 [ "nombre" => "C." "apellidos" => "Taxonera" ] 6 => array:2 [ "nombre" => "P." "apellidos" => "Sánchez-Martínez" ] 7 => array:2 [ "nombre" => "X." "apellidos" => "Martínez-Lacasa" ] 8 => array:2 [ "nombre" => "M." "apellidos" => "García-Gasalla" ] 9 => array:2 [ "nombre" => "J." "apellidos" => "Dorca" ] 10 => array:2 [ "nombre" => "M." "apellidos" => "Arias-Guillén" ] 11 => array:2 [ "nombre" => "J.M." "apellidos" => "García-García" ] 12 => array:2 [ "nombre" => "E." "apellidos" => "Dauden" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219018302324" "doi" => "10.1016/j.adengl.2018.06.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302324?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018301790?idApp=UINPBA000044" "url" => "/00017310/0000010900000007/v1_201809020415/S0001731018301790/v1_201809020415/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219018302294" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.017" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "1898" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2018;109:602-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1 "PDF" => 1 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Practical Dermatology" "titulo" => "Allergic Contact Dermatitis Due to Paraphenylenediamine: An Update" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "602" "paginaFinal" => "609" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Actualización en la dermatitis de contacto alérgica por parafenilendiamina" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 870 "Ancho" => 1300 "Tamanyo" => 96387 ] ] "descripcion" => array:1 [ "en" => "Chronic hyperkeratotic eczema affecting the palm, palmar surface of the fingers, and anterior surface of the wrist in a hairdresser with positive results to paraphenylenediamine and thiuram in patch tests." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "B. Encabo Durán, D. Romero-Pérez, J.F. Silvestre Salvador" "autores" => array:3 [ 0 => array:2 [ "nombre" => "B." "apellidos" => "Encabo Durán" ] 1 => array:2 [ "nombre" => "D." "apellidos" => "Romero-Pérez" ] 2 => array:2 [ "nombre" => "J.F." "apellidos" => "Silvestre Salvador" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018300401" "doi" => "10.1016/j.ad.2017.12.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018300401?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302294?idApp=UINPBA000044" "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018302294/v1_201809020417/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219018301938" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.001" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "1953" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2018;109:582-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Opinion Article" "titulo" => "Ertapenem for the treatment of Hidradenitis suppurativa: how much do we need it?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "582" "paginaFinal" => "583" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Ertapenem para el tratamiento de hidradenitis supurativa: ¿en qué medida lo necesitamos?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Mendes-Bastos, A. Martorell, S. Magina" "autores" => array:3 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Mendes-Bastos" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Martorell" ] 2 => array:2 [ "nombre" => "S." "apellidos" => "Magina" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018301789" "doi" => "10.1016/j.ad.2018.03.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018301789?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301938?idApp=UINPBA000044" "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018301938/v1_201809020417/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "Special article" "titulo" => "Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "584" "paginaFinal" => "601" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "P. Rodríguez-Jiménez, I. Mir-Viladrich, P. Chicharro, G. Solano-López, F.J. López-Longo, C. Taxonera, P. Sánchez-Martínez, X. Martínez-Lacasa, M. García-Gasalla, J. Dorca, M. Arias-Guillén, J.M. García-García, E. Dauden" "autores" => array:13 [ 0 => array:4 [ "nombre" => "P." "apellidos" => "Rodríguez-Jiménez" "email" => array:1 [ 0 => "pedro.rodriguez.jimenez90@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "I." "apellidos" => "Mir-Viladrich" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "P." "apellidos" => "Chicharro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "G." "apellidos" => "Solano-López" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "F.J." "apellidos" => "López-Longo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 5 => array:3 [ "nombre" => "C." "apellidos" => "Taxonera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 6 => array:3 [ "nombre" => "P." "apellidos" => "Sánchez-Martínez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 7 => array:3 [ "nombre" => "X." "apellidos" => "Martínez-Lacasa" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 8 => array:3 [ "nombre" => "M." "apellidos" => "García-Gasalla" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 9 => array:3 [ "nombre" => "J." "apellidos" => "Dorca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 10 => array:3 [ "nombre" => "M." "apellidos" => "Arias-Guillén" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] 11 => array:3 [ "nombre" => "J.M." "apellidos" => "García-García" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "aff0050" ] ] ] 12 => array:3 [ "nombre" => "E." "apellidos" => "Dauden" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:10 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, IIS-FIB, Hospital Universitario de La Princesa. Madrid, España" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Son Llàtzer, Palma de Mallorca, España" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio del Aparato Digestivo, Hospital Clínico San Carlos e Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, España" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona, España" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Unidad Control de Tuberculosis, Hospital Universitari Mutua de Terrassa, Barcelona, España" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Son Llàtzer, Palma de Mallorca, España" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario de Bellvitge, Hospitalet de Llobregat (Barcelona), España" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario Central de Asturias-Instituto Nacional de Silicosis, Oviedo, España" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Servicio de Neumología, Hospital San Agustín, Avilés, España" "etiqueta" => "j" "identificador" => "aff0050" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1998 "Ancho" => 2088 "Tamanyo" => 209567 ] ] "descripcion" => array:1 [ "en" => "Provisional algorithm for assessment of TB infection in candidates for anti-TNF treatment. a Appropriate treatment for TB is defined as ≥6 months of treatment with first-line drugs, including ≥2 months of the combination of rifampicin, isoniazid, pyrazinamide and ethambutol. Appropriate treatment for latent infection can be administration of ≥6 months of isoniazid, 3 months of isoniazid and rifampicin, or 4 months of rifampicin alone. b The risk of latent infection is determined by weighting factors such as exposure to known contagious case, age, country of origin, and work and social history of the individual, including travel to endemic countries and repeated exposure to collectives at risk (closed institutions, homeless, drug users). c In those infected many years earlier, TT can be negative and become positive in a second TT (booster phenomenon). With the availability of IGRAs, it would seem more practical to use these as complementary tests rather than performing a second TT, both in patients aged more than 60 years and in immunosuppressed patients due to different causes, regardless of age. d There are no conclusive data to establish a safe period between the start of treatment for latent infection and the start of anti-TNF therapy. Four weeks delay is considered usual practice and safe by most experts. eActive TB treatment should be completed before starting biological therapy. See text for interpretation and extension of this algorithm. Anti-TNF, anti-tumor necrosis factor; BCG, bacillus Calmette-Guerin; IGRA, interferon γ release assay; TB, tuberculosis; TT, tuberculin test. Source: Adapted from Winthrop..<a class="elsevierStyleCrossRef" href="#bib1200">120</a>" ] ] ] "textoCompleto" => "IntroductionAccording to current estimates, a third of the world population is a carrier of latent Mycobacterium tuberculosis infection,<a class="elsevierStyleCrossRef" href="#bib0605">1</a> which can become reactivated, particularly in immunocompromised patients. The estimated incidence of latent tuberculosis infection (LTI) in Spain in patients with psoriasis treated with anti-tumor necrosis factor (TNF) agents is 29%.<a class="elsevierStyleCrossRef" href="#bib0610">2</a> In the best case scenario, only 10% of those infected will develop active tuberculosis (TB) during their lifetimes.<a class="elsevierStyleCrossRefs" href="#bib0615">3,4</a> However, there are factors that may significantly increase this percentage and so latent infection is considered a major obstacle for worldwide elimination of TB. Public health measures and, ultimately, clinical management of TB infection could be improved if we had a better knowledge of latent and reactivated states of M tuberculosis.On the other hand, in the past 10 years, development of biological therapies as led to a major change in the treatment of some chronic inflammatory skin diseases, and psoriasis in particular, but also hidradenitis suppurativa after the recent approval of adalimumab in that indication. In 1998, the Food and Drug Administration approved the use of infliximab in patients with psoriasis who are refractory to conventional immunomodulatory treatment.<a class="elsevierStyleCrossRef" href="#bib0625">5</a> Since then, more than 20 new drugs have become available for the treatment of immune-mediated inflammatory diseases (IMIDs) in which TNF and its receptors play a key role in acute and chronic inflammatory responses.<a class="elsevierStyleCrossRef" href="#bib0630">6</a>TNF is important for immune response, and so drugs that target this molecule may increase the risk of infections and TB reactivation.Postmarketing surveillance of the first biological agents to be approved (infliximab and etanercept) soon revealed the appearance of associated cases of TB.<a class="elsevierStyleCrossRef" href="#bib0635">7</a> In Spain, since February 2000, a surveillance program with active data acquisition in the Biological Products Database of the Spanish Rheumatology Society (BIOBADASER)<a class="elsevierStyleCrossRef" href="#bib0640">8</a> has been implemented and in October 2008, the Spanish registry of systemic psoriasis treatments (BIOBADADERM) was set up as part of the pharmacovigilance strategy.<a class="elsevierStyleCrossRef" href="#bib0645">9</a>Evidence from reported cases showed a strong association between infliximab therapy and increased risk of active TB. This soon forced guidelines and recommendations to be established such as the one published in 2003 by the Spanish Work Group for Crohn Disease and Ulcerative Colitis (GETECCU),<a class="elsevierStyleCrossRef" href="#bib0650">10</a> for the prevention of TB in candidates for infliximab treatment.Diagnosis of LTI and preventive treatment with isoniazid (INH) for 9 months has been established as a means to reduce the probability of progression to active TB,<a class="elsevierStyleCrossRefs" href="#bib0655">11,12</a> and it has been shown that implementation of LTI screening protocols in candidates for anti-TNF therapy has reduced the incidence of TB by more than 78%.<a class="elsevierStyleCrossRef" href="#bib0665">13</a> However, new cases have continued to arise, even after preventive treatment with INH,<a class="elsevierStyleCrossRef" href="#bib0670">14</a> and this has forced the protocols to be updated and attempts to improve the sensitivity and specificity of the diagnostic tests and treatments in this population, with a high risk of progression to active TB.<a class="elsevierStyleCrossRef" href="#bib0675">15</a>Objectives of the DocumentThe availability of abundant and recent information on new biological therapies and the lack of guidelines agreed among different Spanish scientific societies was the rationale behind the need for a consensus document, published in 2016. This document aimed to collate existing information and recommendations on the basis of evidence available and consensus of a group of experts.<a class="elsevierStyleCrossRef" href="#bib0680">16</a> The objective of the present document is to update and extend the information in the earlier document and adapt it to dermatology patients.MethodologyThe document has been drafted by designated experts from the participating societies (Spanish Academy of Dermatology and Venereology, Spanish Society of Pneumology and Thoracic Surgery, Spanish Society of Digestive Pathology, Spanish Society of Rheumatology, and Spanish Society of Infectious Diseases and Clinical Microbiology) who spend a large part of their time on the study and control of candidates for biological therapies and who have particular experience in this field. The most recent editions of Spanish and international guidelines for biological diseases, diagnosis and treatment of LTI, and databases of Medline and Cochrane up until July 2017 were consulted. With the information obtained, recommendations were established based on the classification of the Infectious Diseases Society of America,<a class="elsevierStyleCrossRef" href="#bib0685">17</a> as well as the strength of the recommendation<a class="elsevierStyleCrossRef" href="#bib0690">18</a> (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Biological Treatments Approved in DermatologyCurrently, the biological agents with an indication approved in Spain for psoriasis are infliximab, etanercept, adalimumab, ustekinumab, secukinumab, and ixekizumab.<a class="elsevierStyleCrossRefs" href="#bib0695">19–31</a> Adalimumab has also recently been approved for the treatment of hidrosadenitis suppurativa.<a class="elsevierStyleCrossRef" href="#bib0760">32</a> There are no other biological agents approved for diseases specifically of the skin. <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> summarizes the main indications for each biological agent and the date of approval in Spain.<a class="elsevierStyleCrossRefs" href="#bib0695">19–24</a><elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Currently, new therapeutic options are emerging for the treatment of psoriasis such as brodalumab<a class="elsevierStyleCrossRef" href="#bib0765">33</a> (IL17 receptor antagonist); guselkumab,<a class="elsevierStyleCrossRef" href="#bib0770">34</a> tildrakizumab<a class="elsevierStyleCrossRef" href="#bib0775">35</a> and risankizumab<a class="elsevierStyleCrossRef" href="#bib0780">36</a> (anti-IL23); and tofacitinib<a class="elsevierStyleCrossRef" href="#bib0785">37</a> (Janus kinase 1 and 3 inhibitor). The biological agents currently available have already been shown to be effective in diseases other than psoriasis (sarcoidosis, lipoid necrobiosis, granuloma annulare, pityriasis rubra pilaris), and some of these may be approved in these indications in the near future.Tuberculosis and Biological TherapyCorticosteroid therapy in systemic diseases and immunosuppressant protocols to prevent graft rejection in transplantation have demonstrated in the past that TB is a real problem for patients treated with immunosuppressants<a class="elsevierStyleCrossRef" href="#bib0790">38</a> (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). The development of active TB in this population is a clear cause for concern: diagnosis may be delayed due to an atypical presentation,<a class="elsevierStyleCrossRefs" href="#bib0635">7,39</a> patients may present with adverse effects due to the underlying diseases or drug interactions, and the potential for TB transmission to the community should not be forgotten, including infection of other immunosuppressed patients who receive similar medical care in shared treatment areas.<elsevierMultimedia ident="tbl0015"></elsevierMultimedia>TNF is a potent modulator of early inflammatory response to a large variety of physical, environmental, infectious, and immunological stimuli. Specifically, TNF is a key part of the body's defense against M tuberculosis and, along with interferon (IFN) γ and other related cytokines, it plays an important role in the development and maintenance of granulomas as structures that compartmentalize and contain the tuberculosis bacillus during infection<a class="elsevierStyleCrossRefs" href="#bib0800">40,41</a> (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). Inhibition of TNF and its regulatory network is the biological basis that appears to explain the 4- to 5-fold increase, on average, in TB incidence in patients with TB infection who receive infliximab.<a class="elsevierStyleCrossRef" href="#bib0640">8</a> Cases of TB have also been reported with other lower affinity TNF inhibitors, such as etanercept, a fusion protein that binds to the soluble portion of the TNF receptor, and adalimumab, a monoclonal antibody like infliximab, but fully human.<a class="elsevierStyleCrossRef" href="#bib0810">42</a> Only exceptionally, and without a clear causal relationship, has ustekinumab, a p40 protein inhibitor of IL12 and IL23, been related with possible reactivation of latent TB.<a class="elsevierStyleCrossRefs" href="#bib0815">43,44</a> IL17 inhibition, in contrast, does not appear to reactivate LTI according to in vitro models.<a class="elsevierStyleCrossRefs" href="#bib0825">45–47</a><elsevierMultimedia ident="fig0005"></elsevierMultimedia>It is believed that granulomas are the structures that contribute to control of the intramacrophagic bacilli, as they provide a local environment in which antigen presenting cells (APCs) and lymphocytes interact to suppress growth and proliferation.<a class="elsevierStyleCrossRef" href="#bib0635">7</a> A large part of the work for determining the TB reactivation mechanisms has focused on the role of TNF in the formation and maintenance of these structures. Bruns et al.,<a class="elsevierStyleCrossRef" href="#bib0840">48</a> however, described an additional mechanism to explain the susceptibility to TB progression in individuals treated with infliximab. In cells from patients with a positive tuberculin test, they identified a subset of effector T cells, denominated CD8+ effector memory T cells (TEMRA), which are memory cells rich in granulysin, a protein with antimycobacterial properties, and they showed that TEMRA are selectively depleted by the effect of infliximab in patients with rheumatoid arthritis (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).<elsevierMultimedia ident="fig0010"></elsevierMultimedia>Cell-based immunity is essential for control of TB infection and, for a long time now, it has been recognized that CD4+ T cells are important mediators of M tuberculosis immunity. More recently, the focus has been on specific CD8+ cells, but the meaning of this finding has yet to be determined, particularly in humans. It is believed that CD8+ cells directly limit growth of mycobacteria by causing death of infected cells,<a class="elsevierStyleCrossRefs" href="#bib0845">49,50</a> and also indirectly, through release of cytokines that promote activation of macrophages and chemokines that coordinate recruitment of other cells. Other studies indicate that CD8+ cells are probably less important during the acute phase of infection by M tuberculosis but essential during the chronic phase, and so they may help prevent TB reactivation.<a class="elsevierStyleCrossRefs" href="#bib0855">51,52</a> On assessment of the contribution of CD8+ cells to M tuberculosis immunity, it is important to remember that mice do not express granulysin, the cytolytic protein that, in humans, contributes to the death of M tuberculosis.<a class="elsevierStyleCrossRef" href="#bib0845">49</a> Thus, studies in murine models may underestimate the importance of the antimycobacterial properties of CD8+ cells if their role is to be extrapolated to human immunity. Fewer studies have been performed in humans, but in vitro experiments show that TEMRA exhibit a high avidity for stains specific to granulysin and show higher levels both of cytotoxicity and antimycobacterial activity compared with other T cell subsets.<a class="elsevierStyleCrossRef" href="#bib0865">53</a>The study by Bruns et al.<a class="elsevierStyleCrossRef" href="#bib0840">48</a> goes beyond the definition of TEMRA as mere effectors with potential antimycobacterial importance, and attempts to explain the consequences of TNF blockade on these cells based on observations of M tuberculosis growth in cell culture. With these observations, an apparently new mechanism is described in which TNF is neutralized, thereby facilitating progression of latent infection to active infection. Previous studies in animal models had shown variable increases in bacillary load in absence of TNF.<a class="elsevierStyleCrossRef" href="#bib0870">54</a> The results of these studies indicated that TNF contributes to direct control of intramacrophagic mycobacteria and indirect suppression of mycobacterial growth by modulating the formation and persistence of granulomas.Risk of Tuberculosis With Anti-TNF AgentsTB infection is caused, in general, by inhalation of viable bacilli that usually persist in an inactive state known as LTI, although occasionally they can progress rapidly leading to active disease. Individuals with LTI remain asymptomatic and are not contagious. In most cases, initial infection by M tuberculosis can be contained by the hosts own defenses and the infection remains latent. However, this situation of latent infection can quickly turn into a disease state at any time.The risk of TB reactivation with use of anti-TNF agents depends on 2 variables: the immunomodulatory effect of treatment and the underlying prevalence of TB infection, or of individuals at risk of infection in a given population. <a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a> presents incidence data published in the first 10 years of use of anti-TNF agents for treatment of rheumatoid arthritis; note, however, that the results cannot necessarily be applied to dermatology patients.<a class="elsevierStyleCrossRefs" href="#bib0790">38,55–57</a><elsevierMultimedia ident="tbl0020"></elsevierMultimedia>Previous treatment for latent infection does not mean the patient is fully protected,<a class="elsevierStyleCrossRef" href="#bib0890">58</a> and no standard period has been established for reactivation; rather, this may vary according to the drug used.<a class="elsevierStyleCrossRef" href="#bib0895">59</a> The Italian multidisciplinary group for the detection of TB in patients receiving biological therapy (SAFEBIO) concluded in their guidelines that etanercept, among all anti-TNF agents, is the one with lowest risk of reactivation of LTI.<a class="elsevierStyleCrossRef" href="#bib0660">12</a>Moreover, there is evidence that exposure to more than 1 anti-TNF drug may double the relative risk of exposure to a single drug for development of serious infections.<a class="elsevierStyleCrossRef" href="#bib0900">60</a>Reinitiating Biological Treatment After Reactivation of TuberculosisIn the cohort study by Ozguler et al.,<a class="elsevierStyleCrossRef" href="#bib0905">61</a> of 2754 patients treated with biological agents identified, 22 cases of active TB during treatment were identified. One of these patients with active disease died within a month due to miliary TB. In 16 of the 21 remaining patients (76%), after initial suspension of treatment, biological therapy was restarted: etanercept in 6 cases and rituximab in 5 cases were the most extensively used drugs. Of patients who restarted therapy, treatment was reinitiated while anti-TB therapy was ongoing in 4 patients, while 12 reinitiated after the course of anti-TB therapy. The median duration of follow-up after restarting treatment was 53 months (range 40-75 months). Only 1 of the patients who had restarted biological treatment presented with a second reactivation. This was satisfactorily treated with anti-TB therapy; subsequent follow-up of 33 months of biological maintenance therapy did not identify any further reactivation of infection. The authors concluded that restarting treatment with anti-TNF drugs, even during TB treatment, appears to be a viable option in patients who have previously developed TB infection during treatment with anti-TNF agents, although careful follow-up and monitoring are required.The French RATIO group published the results of follow-up of 21 patients who had developed TB while receiving anti-TNF therapy.<a class="elsevierStyleCrossRef" href="#bib0910">62</a> In 4 patients, it was necessary to restart biological therapy (in 3 of them during anti-TB treatment) and there was no recurrence of infection after a mean follow-up of 42.7 months. Aislandis et al.<a class="elsevierStyleCrossRef" href="#bib0915">63</a> published a series of 5 patients with rheumatoid arthritis who had developed TB during anti-TNF therapy. In 3 of these, biological therapy had to be restarted, in all cases after completing anti-TB treatment, and there was no recurrence of infection after a mean follow-up of 24 months.Therefore, it seems possible to restart biological therapy in cases of TB reactivation with an appropriate safety margin with respect to start of TB therapy.Diagnostic Techniques for Latent Tuberculosis InfectionInvestigation of possible TB infection in candidates for biological treatment should start with evaluation of the potential risk of exposure to M tuberculosis. The highest-risk groups are summarized in <a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>.<elsevierMultimedia ident="tbl0025"></elsevierMultimedia>In absence of a gold standard for diagnosis of TB infection, current management of patients with autoimmune diseases who are candidates for anti-TNF treatment includes a directed medical history to investigate history of TB or latent infection, whether treated or not; assessment of the risk of exposure to possible active cases; the search for evidence of prior TB in the chest x-ray; and tests to detect LTI (tuberculin test [TT] or interferon-γ release assay [IGRA]).<a class="elsevierStyleCrossRef" href="#bib0920">64</a>Tuberculin TestTT is a measure of delayed hypersensitivity response to intradermal inoculation with a purified protein derivative, a mixture of more than 200 proteins from M tuberculosis. Given that the antigens contained in the purified protein derivative are also present in other mycobacteria, bacillus Calmette and Guerin (BCG) vaccination may also lead to false positives. Moreover, TT sensitivity is compromised in patients receiving immunosuppressive treatment, with a high rate of false negatives.<a class="elsevierStyleCrossRef" href="#bib0925">65</a> Studies in patients with rheumatoid arthritis have shown that the rate of TT false negatives can be as high as 40%.<a class="elsevierStyleCrossRef" href="#bib0930">66</a> At times, repetition of the TT may be indicated to increase its sensitivity due to the booster effect on false negatives, but this also reduces its specificity, as it increases the number of false positives due to BCG vaccination and exposure to non-TB mycobacteria.<a class="elsevierStyleCrossRef" href="#bib0935">67</a> Logistical drawbacks, including the need for a visit for the readout, and observer subjectivity on recording the result of the test may also impact its efficiency.According to some authors, given that almost all candidates for anti-TNF treatment are receiving (or have received) another immunosuppressive agent, TT would not be the ideal test for LTI screening in patients with inflammatory diseases.<a class="elsevierStyleCrossRef" href="#bib0635">7</a>The TT should never be repeated in patients with a positive result, as it will continue to be positive in most cases. There is a potential risk of severe reactions on repetition of the test while no clinical benefit is expected.Tests Based on Interferon γ Release AssaySequencing of the M tuberculosis genome enabled better identification of the genes involved in its pathogenesis and awareness of the presence of regions of differing genetics. In the region known as RD1, proteins specific to M tuberculosis are secreted (ESAT-6 and CFP-10). These proteins act as specific antigens, inducing a Th1 type immune response with IFN-γ production in patients with M tuberculosis infection. This region, absent in all strains of Mycobacterium bovis-BCG and in almost all non-TB mycobacteria, except for Mycobacterium kansasii, Mycobacterium marinum, and Mycobacterium szulgai, is present in all known virulent strains of M tuberculosis.IGRA techniques are therefore based on detection, in peripheral blood of infected individuals, of IFN-γ released by sensitized T cells in response to in vitro stimulation with M tuberculosis specific antigens. Two IGRA kits are currently available.<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">-QuantiFERON®-TB-Gold in tube (Cellestis Ltd., Carnegie, Australia)<a class="elsevierStyleCrossRef" href="#bib0940">68</a> determines the total production of IFN-γ in infected individuals using an ELISA technique. A value of 0.35 IU/mL is considered positive.</li><li class="elsevierStyleListItem" id="lsti0010">-T-SPOT.TB® (Oxford Immunotec Ltd., UK)<a class="elsevierStyleCrossRef" href="#bib0945">69</a> was developed by Lalvani at the end of the 1990s. The procedure for this kit is more laborious and requires prior separation of monocyte cells before incubation with ESAT-6 and CFP-10 antigens. The reading is done by the Elispot technique, in which each visible spot represents an IFN-γ secreting T cell. The result is considered positive if more than 6 spots are present.</li></ul>Both techniques incorporate positive and negative controls able to detect false results due to anergy and immunological problems (reported as indeterminate results).<a class="elsevierStyleCrossRef" href="#bib0950">70</a> In most guidelines, indeterminate results, which occur more frequently in patients with IMID, should be repeated and these are often confirmed as negative.<a class="elsevierStyleCrossRefs" href="#bib0955">71,72</a>The use of IGRA has a series of advantages over TT:<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015">1.Subjectivity in the interpretation of the results is avoided.</li><li class="elsevierStyleListItem" id="lsti0020">2.The assay can be repeated if necessary.</li><li class="elsevierStyleListItem" id="lsti0025">3.A reading visit at 48-72hours is not needed to obtain the result.</li><li class="elsevierStyleListItem" id="lsti0030">4.Standardization and laboratory application are easy.</li><li class="elsevierStyleListItem" id="lsti0035">5.Positive controls can be included when anergic patients are detected.</li><li class="elsevierStyleListItem" id="lsti0040">6.The patient's privacy is respected.</li></ul>Among the drawbacks, the most important is the cost, which is higher than for the TT. To reduce costs, depending on the capacity of the laboratory, assays can be delayed a reasonable time to enable batch analysis of as many samples as possible at the same time. In any case, implantation of this technique represents a diagnostic improvement and can spare health resources. Its greater specificity decreases the number of false positives compared with TT and, therefore, the costs derived from X-rays, visits, and unnecessary treatment for TB infection. On the other hand, it appears to be more sensitive than TT in those individuals with altered cell immunity at greatest risk of developing TB.<a class="elsevierStyleCrossRefs" href="#bib0965">73,74</a>Interpretation of the Results in Candidates for Biological TreatmentsIGRAs are used as routine tests for diagnosis of latent infection in the United States of America, Canada, Australia, Japan, and some western European countries (United Kingdom, Italy, Germany, and Switzerland). Some countries use them instead of the TT, whereas others use them in combination. In Spain, it is recommended to complement the TT with IGRA to rule out false positives in candidates for chemoprophylaxis with prior BCG vaccination (to rule out false positives to tuberculin) and in those with a negative skin patch test and suspected immunosuppression (to rule out a false negative TT)<a class="elsevierStyleCrossRef" href="#bib0975">75</a> (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).<elsevierMultimedia ident="fig0015"></elsevierMultimedia>Although numerous articles have been published in recent years, data on the performance of these tests are limited and contradictory.<a class="elsevierStyleCrossRefs" href="#bib0970">74–80</a> The data from those studies enable the conclusion that: a) agreement between TT and IGRA is weaker in patients with systemic inflammatory diseases than in healthy subjects due to the lower prevalence of positive TT in the first group<a class="elsevierStyleCrossRefs" href="#bib0930">66,81–86</a>; b) the extent of tuberculin response is significantly lower in patients than in healthy controls<a class="elsevierStyleCrossRef" href="#bib0930">66</a>; c) discordance between TT+ and IGRA- is observed in vaccinated patients; d) discordance between TT- and IGRA+ is often observed in patients receiving corticosteroid therapy<a class="elsevierStyleCrossRef" href="#bib1030">86</a> (<a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a>).<elsevierMultimedia ident="tbl0030"></elsevierMultimedia>Due to the vulnerability of these patients to TB when they are receiving anti-TNF treatment, it seems prudent to perform the 2 tests (TT and IGRA) in parallel to maximize diagnostic sensitivity of screening, at least, until evidence of the utility of IGRA in this population has been consolidated. It is important to mention that when the 2 tests are performed sequentially, IGRAs should be performed first due to the booster effect of the TT.<a class="elsevierStyleCrossRefs" href="#bib1035">87,88</a> It is not known how long the booster effect persists and whether it depends on the quantity of purified protein derivative administered or its characteristics.Given that some patients with latent infection may have false negatives for IGRAs and true positives for TT, and vice versa, the dual screening strategy would enable clinicians to offer preventive treatment to all patients with latent infection (<a class="elsevierStyleCrossRef" href="#tbl0035">Table 7</a>).<elsevierMultimedia ident="tbl0035"></elsevierMultimedia>The results of the IGRAs in patients who are in treatment with anti-TNF agents remain difficult to interpret. One proposed strategy was to repeat the tests after starting biological therapy to detect false negatives. The available data from recent studies<a class="elsevierStyleCrossRefs" href="#bib1045">89–91</a> show conversions and reversions in both tests related to reproducibility problems and changes in the patients¿ immune status. Given this variability, it is not recommended to repeat the test for follow-up of patients during treatment.Treatment of Latent Tuberculosis InfectionThe identification and treatment of LTI greatly reduces the risk of reactivation and, thus, has the potential to protect the health of infected individuals as well as preventing further infection by reducing the number of possible sources of contagion.<a class="elsevierStyleCrossRefs" href="#bib1060">92,93</a>After treatment of LTI, the durability of protection against reactivation is variable and depends on the prevalence of TB in the area and the risk of re-exposure. It is assumed that treatment for LTI can confer lifelong protection against disease. Among Eskimos in Alaska, for example, the protective effect of isoniazid (INH) has been shown to last more than 20 years.<a class="elsevierStyleCrossRefs" href="#bib1070">94,95</a>The treatment of latent infection is only started once active TB has been excluded.Regimens for LTI treatment include INH for 9 months, rifampicin (RIF) monotherapy for 4 months, or INH with RIF for 3 months.<a class="elsevierStyleCrossRef" href="#bib1080">96</a>Isoniazid for 9 MonthsThe INH dose used is 5mg/kg/d with a maximum of 300mg/d in adults. In children under 16 years of age, the dose used should be 10mg/kg/d. The efficacy of INH for reducing the incidence of active TB (compared with placebo) is between 60% and 90%. However, given that not all patients complete the treatment course, the efficacy of treatment is only approximately 60% on average.<a class="elsevierStyleCrossRef" href="#bib1070">94</a>The only study that compares the efficacy of different durations of INH treatment showed efficacy was 65% for the 6 month regimen and 75% for the 12 month regimen (although the difference was not statistically significant). By extrapolation of the data from randomized trials, the optimum duration of INH treatment for LTI was considered to be 9 months, as the study showed similar efficacy values from 9 months onwards.<a class="elsevierStyleCrossRefs" href="#bib1070">94,97</a>The most important side effect of INH is hepatitis, with an incidence of 8%. Most cases are asymptomatic and associated with slight liver enzyme elevations that do not usually exceed 10 times the upper limit of normal.<a class="elsevierStyleCrossRefs" href="#bib1090">98,99</a> The most important risk factor for development of INH-induced hepatitis is alcohol consumption. Patients should be advised to abstain from alcohol consumption while they are taking INH. Peripheral neuropathy presents in up to 2% of patients who take INH.<a class="elsevierStyleCrossRef" href="#bib1100">100</a> This is caused by interference in pyridoxine metabolism and can be prevented by pyridoxine supplements (25 and 50mg/d). This is particularly important for patients with conditions that may predispose them to neuropathy (including diabetes, uremia, alcohol abuse, malnutrition, human immunodeficiency virus infection) as well as pregnant patients with a prior history of convulsions. Pyridoxine should also be administered to babies of breast-feeding mothers who receive INH. Spain has INH formulations that already include vitamin B6, and so this problem is minimized.The preferred treatment regimen for most individuals with LTI is INH daily for 9 months, as recommended by the Centers for Disease Control (CDC).<a class="elsevierStyleCrossRefs" href="#bib1060">92,101</a> A 6-month course of INH also provides substantial protection. In the context of adherence concerns, clinicians may opt to concentrate their efforts in guaranteeing 6 months of therapy. However, regimens shorter than 9 months are not recommended for children or for patients with fibrotic lesions in chest X-ray or in immunosuppressed patients. For patients with poor adherence to treatment, directly observed therapy may be the preferred approach, with administration once or twice a week.Rifampicin for 4 MonthsThe usual dose is 10mg/kg/d with a maximum of 600mg/d. The efficacy of RIF for reducing the incidence of active TB is estimated to be similar to INH.<a class="elsevierStyleCrossRefs" href="#bib1110">102,103</a> Although data are limited, RIF appears to be well-tolerated, with a low rate of hepatotoxicity.<a class="elsevierStyleCrossRef" href="#bib1110">102</a> The drawbacks to routine adoption of RIF for the treatment of latent TB infection include the possibility of underdiagnosing cases of active TB that could then relapse with strains resistant to RIF. Although this could also occur in cases treated with INH, surprisingly, the incidence of relapse with INH has been very low.<a class="elsevierStyleCrossRef" href="#bib1120">104</a> Interactions with other drugs and its elevated price have also been factors for concern in the case of RIF. Thus, there are important and potentially prolonged interactions with other drugs, including warfarin, oral contraceptives, certain antihypertensive agents, antiarrhythmic agents, antidepressants and anticonvulsants, methadone, and the protease inhibitor class of antiretrovirals.<a class="elsevierStyleCrossRefs" href="#bib1125">105,106</a>Isoniazid and Rifampicin for 3 MonthsData on the use of INH and RIF together are limited, but some studies have shown that the combination is an effective regimen with good adherence and well tolerated.<a class="elsevierStyleCrossRef" href="#bib1135">107</a> A meta-analysis of small studies showed that it is just as effective and no more toxic than the 9-month regimen with INH.<a class="elsevierStyleCrossRef" href="#bib1140">108</a> In a prospective, randomized study in individuals infected by the human immunodeficiency virus, a regimen of 3 months of INH and RIF daily offered 60% protection.<a class="elsevierStyleCrossRef" href="#bib1145">109</a>Finally, the combination of RIF with pyrazinamide should not be used for the treatment of ILT, due to the possibility of severe hepatotoxicity.<a class="elsevierStyleCrossRef" href="#bib1080">96</a>Treatment of Latent Tuberculosis Infection in Multidrug Resistant StrainsFor exposed patients who supposedly are infected with mycobacteria resistant to multiple agents, treatment of LTI should be individualized, based on the susceptibility profile of the index case.<a class="elsevierStyleCrossRefs" href="#bib1150">110,111</a> Two drugs should always be chosen to which the organism is susceptible, for example, a combination of pyrazinamide and ethambutol or a fluoroquinolone with antituberculous activity (such as levofloxacin).<a class="elsevierStyleCrossRef" href="#bib1160">112</a> The duration of treatment has not been defined, although from 6 to 12 months seems to be the most reasonable. Patients with LTI due to multidrug resistant strains should receive carefully monitored treatment and be followed closely due to the risk of liver toxicity. In the case of extreme multidrug-resistant strains, with resistance to several drugs, prophylaxis in contacts may be very difficult and no regimens have been tested beyond the first-line drugs.Monitoring of Treatment for Latent Tuberculosis InfectionPatients in treatment for LTI should be supervised monthly with clinical examination and liver testing. Patients should also be educated about the symptoms of hepatitis and instructed to suspend treatment and seek medical attention quickly to reduce the risk of progression to serious disease.<a class="elsevierStyleCrossRef" href="#bib1165">113</a>Treatment of LTI should be discontinued in symptomatic patients with serum transaminase levels in excess of 3 times the upper limit of normal or in asymptomatic patients with serum transaminase levels more than 5 times the upper limit of normal. Treatment should not be restarted under any circumstances.A common dilemma is whether to continue LTI treatment after having started complete treatment for suspicion of active TB which is finally not confirmed (negative cultures or histology). The duration of combination therapy in the initial phase administered may apply to the total duration of treatment for LTI. Subsequent options include interrupting treatment if RIF and pyrazinamide have been given for less than 2 months, continuing treatment with RIF for a total of 4 months (with or without INH), or continuing with INH treatment for a total of 9 months.<a class="elsevierStyleCrossRef" href="#bib1170">114</a>In the case of regimens with INH (9 or 6 months), treatment can be restarted where it was left off if less than 3 months have been lost. Treatment for LTI should be reinitiated from the start if more than 3 months have elapsed. For treatment of LTI with regimens of 3 or 4 months, treatment can be restarted from where it left off if less than 2 months of the course remain.Treatment of Latent Tuberculosis Infection in Candidates for Biological TherapiesThe CDC recommends treatment of LTI of all patients who are planning to take a TNF inhibitor and who have a positive TT result (induration ≥5mm) or a positive IGRA result<a class="elsevierStyleCrossRefs" href="#bib1175">115,116</a> and in the case of patients with negative TT or IGRA but with evidence of previous TB disease in the chest X-ray (for example, regional fibrosis with or without enlarged hilar lymph nodes) or if there is epidemiological evidence of prior exposure to TB (for example, after having been in close contact with a TB case).Patients who are candidates to receive anti-TNF agents with an indication for LTI treatment in general should receive standard therapy, that is, INH for 9 months. The recommendation about what the duration of therapy for LTI should be before starting anti-TNF has not been established, but most authors propose that patients should receive at least 1 month of treatment for LTI before starting anti-TNF therapy, whenever this is possible.<a class="elsevierStyleCrossRefs" href="#bib0670">14,117</a>Treatment with LTI will not protect against TB in the case of recently acquired infection except, perhaps, during the time that the treatment is administered. Therefore, patients who take anti-TNF agents should avoid exposure to TB (for example, occupational exposure such as in health centers with a high prevalence of TB, homeless shelters, prisons, travel to regions with a high prevalence of TB). Treatment with INH of latent infection will likewise not protect against reactivation of the infection by INH-resistant strains.<a class="elsevierStyleCrossRef" href="#bib1190">118</a> There are no studies to enable recommendation of combined regimens of LTI treatment in these patients, although the RIF plus INH regimen has been used by expert groups in a large number of patients, without having detected cases of active TB after starting treatment.Recommendations of the Consensus Document<a class="elsevierStyleCrossRef" href="#tbl0040">Table 8</a> summarizes the recommendations of the panel of experts from the scientific societies participating in this multidisciplinary consensus document. The aim is to guide dermatology specialists in the assessment of risk of developing TB and to prevent disease through the diagnosis and treatment of LTI.<elsevierMultimedia ident="tbl0040"></elsevierMultimedia><a class="elsevierStyleCrossRef" href="#fig0020">Figure 4</a> shows the algorithm proposed for assessment of TB infection in candidates for biological therapy.<a class="elsevierStyleCrossRefs" href="#bib1195">119,120</a><elsevierMultimedia ident="fig0020"></elsevierMultimedia>Conflicts of InterestEsteban Daudén declares he is a member of advisory boards, consultant, grant recipient, research support recipient, participant as an investigator in clinical trials, and recipient of fees for talks with the following pharmaceutical companies: Abbvie (Abbott), Amgen, Janssen-Cilag, Leo Pharma, MSD, Pfizer, Novartis, Celgene, and Lilly.Carlos Taxonara Samso declares he is a consultant and speaker for MSD, AbbVie, Jannsen, Takeda, and Pfizer.Francisco Javier López Longo declares having been an occasional speaker for Abbvie, Actelion, Bristol-Myers-Squibb, GSK, MSD, Pfizer, Roche Farma, and UCB and having received research funding from Abbvie and GSK.The remaining authors declare that they have no conflicts of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:18 [ 0 => array:3 [ "identificador" => "xres1077270" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1023294" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1077269" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1023295" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Objectives of the Document" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Methodology" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Biological Treatments Approved in Dermatology" ] 8 => array:3 [ "identificador" => "sec0025" "titulo" => "Tuberculosis and Biological Therapy" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0030" "titulo" => "Risk of Tuberculosis With Anti-TNF Agents" ] 1 => array:2 [ "identificador" => "sec0035" "titulo" => "Reinitiating Biological Treatment After Reactivation of Tuberculosis" ] ] ] 9 => array:3 [ "identificador" => "sec0040" "titulo" => "Diagnostic Techniques for Latent Tuberculosis Infection" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0045" "titulo" => "Tuberculin Test" ] 1 => array:2 [ "identificador" => "sec0050" "titulo" => "Tests Based on Interferon γ Release Assay" ] ] ] 10 => array:2 [ "identificador" => "sec0055" "titulo" => "Interpretation of the Results in Candidates for Biological Treatments" ] 11 => array:3 [ "identificador" => "sec0060" "titulo" => "Treatment of Latent Tuberculosis Infection" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "Isoniazid for 9 Months" ] 1 => array:2 [ "identificador" => "sec0070" "titulo" => "Rifampicin for 4 Months" ] 2 => array:2 [ "identificador" => "sec0075" "titulo" => "Isoniazid and Rifampicin for 3 Months" ] ] ] 12 => array:2 [ "identificador" => "sec0080" "titulo" => "Treatment of Latent Tuberculosis Infection in Multidrug Resistant Strains" ] 13 => array:2 [ "identificador" => "sec0085" "titulo" => "Monitoring of Treatment for Latent Tuberculosis Infection" ] 14 => array:2 [ "identificador" => "sec0090" "titulo" => "Treatment of Latent Tuberculosis Infection in Candidates for Biological Therapies" ] 15 => array:2 [ "identificador" => "sec0095" "titulo" => "Recommendations of the Consensus Document" ] 16 => array:2 [ "identificador" => "sec0100" "titulo" => "Conflicts of Interest" ] 17 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2017-11-04" "fechaAceptado" => "2018-03-19" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1023294" "palabras" => array:5 [ 0 => "Psoriasis" 1 => "Hidradenitis suppurativa" 2 => "Biologic therapy" 3 => "Tuberculosis" 4 => "Consensus" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1023295" "palabras" => array:5 [ 0 => "Psoriasis" 1 => "Hidrosadenitis supurativa" 2 => "Terapias biológicas" 3 => "Tuberculosis" 4 => "Consenso" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Patients with chronic inflammatory diseases being treated with immunosuppressive drugs, and with tumor necrosis factor inhibitors in particular, have an increased risk of infection by Mycobacterium tuberculosis. Screening for latent tuberculosis infection and preventive therapy to reduce the risk of progression to active tuberculosis are mandatory in this group of patients. This updated multidisciplinary consensus document presents the latest expert opinions on the treatment and prevention of tuberculosis in candidates for biologic therapy and establishes recommendations based on current knowledge relating to the use of biologic agents." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "El riesgo de infección por Mycobacterium tuberculosis se halla aumentado en los pacientes con enfermedades inflamatorias crónicas y en tratamiento inmunosupresor, en particular con terapia antifactor de necrosis tumoral α. La detección de la infección tuberculosa latente y el tratamiento preventivo dirigido a reducir el riesgo de progresión a tuberculosis activa es obligatoria en este grupo de pacientes. Este documento de consenso multidisciplinar actualiza la opinión de expertos y establece recomendaciones para el diagnóstico y tratamiento de la infección tuberculosa latente en estos pacientes, según los conocimientos actuales en terapias biológicas." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Rodríguez-Jiménez P, Mir-Viladrich I, Chicharro P, Solano-López G, López-Longo FJ, Taxonera C, et al. Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico. Actas Dermosifiliogr. 2018;109:584–601." ] ] "multimedia" => array:12 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1480 "Ancho" => 2321 "Tamanyo" => 174867 ] ] "descripcion" => array:1 [ "en" => "Graphical representation of the extensive involvement of TNF in immune response to M tuberculosis infection." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2665 "Ancho" => 2167 "Tamanyo" => 294523 ] ] "descripcion" => array:1 [ "en" => "In absence of anti-TNF, cytotoxic effector memory T cells (TEMRA) release granulomas with cytolytic enzymes (perforin, granulysin) that destroy macrophages infected by M tuberculosis as well as intra- and extracellular bacilli. In presence of anti-TNF, transmembrane TNF of TEMRA is bound to this antibody, favoring lymphocyte apoptosis. Depletion of cytotoxic T cells therefore prevents growth control and allows dissemination of M tuberculosis. Source: Adapted from Miller and Ernst.<a class="elsevierStyleCrossRef" href="#bib0805">41</a>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 891 "Ancho" => 2088 "Tamanyo" => 96337 ] ] "descripcion" => array:1 [ "en" => "BCG, bacillus Calmette-Guerin; IGRA, interferon γ release assay. a Patients with CD4+ counts ≥ 500 cells/mL are considered immunocompetent. b In cases of severe immunosuppression (CD4+ count < 200 cells/mL), the probability of true infection should be assessed individually. c IGRA measurement can be repeated periodically (depending on the individual risk in each patient) without any booster effect. Source: Adapted from the Diagnostic and Treatment Guidelines for Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)..<a class="elsevierStyleCrossRef" href="#bib0975">75</a>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1998 "Ancho" => 2088 "Tamanyo" => 209567 ] ] "descripcion" => array:1 [ "en" => "Provisional algorithm for assessment of TB infection in candidates for anti-TNF treatment. a Appropriate treatment for TB is defined as ≥6 months of treatment with first-line drugs, including ≥2 months of the combination of rifampicin, isoniazid, pyrazinamide and ethambutol. Appropriate treatment for latent infection can be administration of ≥6 months of isoniazid, 3 months of isoniazid and rifampicin, or 4 months of rifampicin alone. b The risk of latent infection is determined by weighting factors such as exposure to known contagious case, age, country of origin, and work and social history of the individual, including travel to endemic countries and repeated exposure to collectives at risk (closed institutions, homeless, drug users). c In those infected many years earlier, TT can be negative and become positive in a second TT (booster phenomenon). With the availability of IGRAs, it would seem more practical to use these as complementary tests rather than performing a second TT, both in patients aged more than 60 years and in immunosuppressed patients due to different causes, regardless of age. d There are no conclusive data to establish a safe period between the start of treatment for latent infection and the start of anti-TNF therapy. Four weeks delay is considered usual practice and safe by most experts. eActive TB treatment should be completed before starting biological therapy. See text for interpretation and extension of this algorithm. Anti-TNF, anti-tumor necrosis factor; BCG, bacillus Calmette-Guerin; IGRA, interferon γ release assay; TB, tuberculosis; TT, tuberculin test. Source: Adapted from Winthrop..<a class="elsevierStyleCrossRef" href="#bib1200">120</a>" ] ] 4 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " colspan="3" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Strength of Recommendation</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Recommendations by Scientific Quality</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Strong \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Recommendation supported \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Grade I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Recommendation based on at least 1 randomized, controlled clinical trial with an appropriate design \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Recommendation supported \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Grade II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Recommendation based on at least 1 trial with an appropriate design but not randomized, cohort studies, multiple series, or very evident results in uncontrolled trials. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Weak \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Recommendation cannot be either supported or rejected \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Grade III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Recommendation based on expert opinion in descriptive studies or in clinical experience \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838849.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Degree of Recommendation<a class="elsevierStyleCrossRef" href="#bib0690">18</a>" ] ] 5 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Abbreviations; CHO, Chinese hamster ovary; TNF, tumor necrosis factor." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Treatment \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Type of Biological Agent \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Indication Date of approval \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Infliximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Chimeric IgG1 human-mouse IgG1 monoclonal anti-TNF antibody produced in murine hybridoma cells by recombinant DNA technology. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies. August 1999 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Etanercept</td><td class="td" title="table-entry " align="left" valign="top">Dimeric fusion protein of soluble extracellular domain of human TNF receptor 2 and Fc domain of human IgG1 produced by recombinant DNA techniques from a CHO cell culture \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies. February 2000 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Severe chronic plaque psoriasis in children from 6 years of age whose disease is not controlled or who are intolerant to other systemic therapies. February 2009 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Adalimumab</td><td class="td" title="table-entry " align="left" valign="top">Recombinant human monoclonal anti-TNF antibody produced in CHO cells \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies. September 2003 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Severe chronic plaque psoriasis in children from 4 years of age whose disease is not controlled or who are intolerant to other systemic therapies. April 2015 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Patients at least 12 years of age with active moderate to severe hidrosadenitis suppurativa who do not respond appropriately to other conventional systemic treatments. September 2015 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ustekinumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anti-p40 human monoclonal antibody (IL12/23 subunit) that is produced in a mouse myeloma cell line using recombinant DNA technology. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies. January 2009 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Secukinumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fully human anti-IL-17, IgG1/κ monoclonal antibody, produced in CHO cells \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Treatment of moderate to severe psoriasis vulgaris in adult candidates for systemic treatments. March 2016 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ixekizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fully human anti-IL-17, IgG1/κ monoclonal antibody, produced in CHO cells \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Treatment of moderate to severe psoriasis vulgaris in adult candidates for systemic treatments. March 2017 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838845.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Type of Biological Agent, Indication, and Date of Approval." ] ] 6 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Abbreviations: TC, T-cell; TNF, tumor necrosis factor." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Classification Effect \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drugs \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Indications \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Theoretical Risk of TB \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Lymphoblastic Destruction of lymphoid tissue \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alkylating Agents Cyclophosphamide Fludarabine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Chemotherapy Systemic diseases \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">± \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antimetabolites Inhibition of synthesis of purines and pyrimidines Blockade of activated TC expansion \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mycophenolate mofetil Azathioprine Methotrexate Leflunomide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Prevention of graft rejection Systemic diseases \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">+ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiproliferative Agents control entry into S phase of the cell cycle by binding to the rapamycin receptor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sirolimus Everolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Prevention of graft rejection  \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">+ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Anticalcineurin Agents inhibit TC activation signal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cyclosporin A Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Prevention of graft rejection  \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">+ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Corticosteroids Agents inhibit all immunoinflammatory reactions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Prednisone Methylprednisolone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Systemic diseases Prevention of graft rejection Oncology Asthma, hypersensitivity pneumonitis, diffuse interstitial fibrosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">++ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Anti-TNF These inhibit TNF proinflammatory cytokines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Infliximab Adalimumab Etanercept Golimumab Certolizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"> Systemic diseases \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">+++ \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838846.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Immunosuppressants That May Induce Tuberculosis." ] ] 7 => array:8 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at4" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "Abbreviations: RA, rheumatoid arthritis; RR, relative risk; TNF, tumor necrosis factor." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Incidence/100 000 and RR of Tuberculosis \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Spain Gómez-Reino et al. (2003<a class="elsevierStyleCrossRef" href="#bib0640">8</a>), Carmona et al. (2005)<a class="elsevierStyleCrossRef" href="#bib0665">13</a> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">USA Wolfe et al. (2004)<a class="elsevierStyleCrossRef" href="#bib0875">55</a> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sweden Askling et al. (2005)<a class="elsevierStyleCrossRef" href="#bib0885">57</a> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Korea Seong et al. (2007)<a class="elsevierStyleCrossRef" href="#bib0880">56</a> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In the general population (RR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25 (1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.2 (1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4-14<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a>(2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">67 (1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In RA (RR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">110 (4.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">118 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">257 (4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In RA with anti-TNF (cumulative RR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">20×5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">24.5 (4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8×4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">36×9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In RA with anti-TNF with recommendations (RR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">117 (4.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.2 (1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Effectiveness \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Proven \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Proven \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Proven \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838847.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Incidence of hospitalization due to TB." ] ] ] "descripcion" => array:1 [ "en" => "Incidence and Relative Risk of Tuberculosis in Rheumatoid Arthritis Before and After Introduction of Anti-TNF Agents: Impact of the Recommendations." ] ] 8 => array:8 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at5" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Abbreviation: HIV, human immunodeficiency virus." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Persons in recent contact with patients with TB disease \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Persons born or who live in countries with a high prevalence of TB or those who travel frequently to such countries for business, family, or humanitarian reasons \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Residents and workers in closed institutions such as prisons, hostels for the destitute, and social and health centers of any type \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Abuse of alcohol and other harmful substances, while not forgetting that smokers develop TB more frequently than nonsmokers \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Health workers, in particular those who attend patients with active TB \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Persons with radiologic lesions suggestive of old TB, particularly if, as in the case of positive tuberculin, they have never received treatment \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Very old and very young people, immunosuppressive diseases, and other comorbid conditions usually associated with increased risk of TB. This group includes patients with HIV infection, autoimmune diseases, and post-transplantation period, but also includes lung diseases (silicosis), chronic kidney disease, gastrectomy, diabetes, and certain tumors such as those of the head and neck \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838851.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Groups at High Risk of Conversion to Active Tuberculosis." ] ] 9 => array:8 [ "identificador" => "tbl0030" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at6" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Abbreviations: Anti-TNF, anti-tumor necrosis factor; BCG, bacillus Calmette-Guerin; HIV, human immunodeficiency virus; IGRA, interferon γ release assay; QF, Quantiferon; TB, tuberculosis; TT, tuberculin test." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Study \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Test \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">No. of Patients \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Findings \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ponce de León et al. (2005)<a class="elsevierStyleCrossRef" href="#bib0925">65</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-In Tube \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">101 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The percentage of TT positive patients was significantly lower in patients with inflammatory disease than in healthy controls and induration was also significantly less extensive \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Pratt et al. (2007)<a class="elsevierStyleCrossRef" href="#bib0950">70</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-Gold \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">101 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">98 patients (4 of them with QF-G positive result) received anti-TNF treatment with no documented cases of active TB after 30 months of follow-up \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Takahashi et al. (2007)<a class="elsevierStyleCrossRef" href="#bib1005">81</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-Gold \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Agreement between conventional study (TT, chest X-ray, medical history) and QF-G was moderate (64.3%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cobanoglu et al. (2007)<a class="elsevierStyleCrossRef" href="#bib1020">84</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-In Tube \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">68 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Agreement between TT and T-SPOT was lower in healthy controls (64%) and very low in patients with inflammatory diseases (47%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sellam et al. (2007)<a class="elsevierStyleCrossRef" href="#bib1025">85</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">T-SPOT.TB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Agreement between TT and T-SPOT in patients with documented TB infection (radiographic abnormalities, prior TB) was moderate (71%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Boccino et al. (2008)<a class="elsevierStyleCrossRef" href="#bib0995">79</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-In Tube, T-SPOT.TB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">66 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8/15 patients with inflammatory diseases and risk factors for TB were positive for TT, QF, and T-SPOT. The remaining 7 were negative for TT, but positive for QF or T-SPOT. 31/35 patients with no risk factors negative for all tests \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Matulis et al. (2008)<a class="elsevierStyleCrossRef" href="#bib1015">83</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-In Tube \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">142 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-IT was more closely associated with having risk factors for TB. The agreement between TT and T-SPOT was low (64%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Vassilopoulos et al. (2008)<a class="elsevierStyleCrossRef" href="#bib1010">82</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">T-SPOT.TB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">70 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The agreement between TT and T-SPOT was moderate (72%). In the multivariate analysis, BCG vaccination was associated with a higher % of TT+ and corticosteroids with a higher % of T-SPot+ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Santin et al. (2012)<a class="elsevierStyleCrossRef" href="#bib0965">73</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QF-In Tube, T-SPOT.TB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"> 6514 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Meta-analysis (38 studies), IGRA: limited capacity for ruling out TB in HIV+ patients. Positive results are influenced by the disease load of the population studied \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838848.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Results of Screening Tests for Latent Tuberculosis Infection in Patients with Systemic Inflammatory Diseases." ] ] 10 => array:8 [ "identificador" => "tbl0035" "etiqueta" => "Table 7" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at7" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressed</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Without Taking Into Account BCG vaccination Status</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TT < 5mm \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TT ≥ 5 mm \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">IGRA negative (IN) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No LTI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">LTI \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">IGRA positive (IP) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">LTI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">LTI \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">IGRA indeterminate (II) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">?<a class="elsevierStyleCrossRef" href="#tblfn0010">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">LTI \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838852.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "a" "nota" => "Immunosuppressed patients with 1 or 2 positive screening tests should receive treatment for LTI with any of the recommended regimens. Doubtful or indeterminate results should be repeated (complement TT with IGRA or T-SPOT.TB). Abbreviations: IGRA interferon γ release assay; LTI latent tuberculosis infection; TT tuberculin test." ] ] ] "descripcion" => array:1 [ "en" => "Interpretation of the Results of Screening in Immunosuppressed Patients." ] ] 11 => array:8 [ "identificador" => "tbl0040" "etiqueta" => "Table 8" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at8" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Abbreviations: CT, computed tomography; IGRA, interferon γ release assay; IMID, immune-mediated inflammatory disease; INH, isoniazid; LTI, latent tuberculosis infection; TNF, tumor necrosis factor, RIF, rifampicin; TB, tuberculosis; TT, tuberculin test." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">All candidates for biological therapies should be studied for diagnosis of LTI as these patients belong to one of the highest risk groups for developing TB.<a class="elsevierStyleCrossRefs" href="#bib0640">8,9</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">The risk of these patients falling ill appears to be depend on the anti-TNF agent used: infliximab and adalimumab are those with highest risk detected<a class="elsevierStyleCrossRefs" href="#bib0640">8,42</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="3" align="left" valign="top">The diagnostic methods for LTI detection are based on<a class="elsevierStyleCrossRef" href="#bib0975">75</a>:</td><td class="td" title="table-entry " align="left" valign="top">Active search for TB history in the patient's medical record as well as contacts with active TB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Chest X-ray can detect possible old TB lesions. In the case of doubt, it is advised to complete the study with chest CT, given that this technique is superior to chest X-ray for detection of early radiologic signs of active TB or old lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Simultaneous performance of IGRA and TT. Any positive result in one of these tests is considered indicative of LTI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Patients diagnosed with IMIDs have a higher rate of false negatives with TT and IGRA.<a class="elsevierStyleCrossRefs" href="#bib0955">71,72</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">There is no evidence that repeating TT (booster effect) increases the sensitivity of the test in patients with IMID but that it does reduce specificity, and so currently, with the use of IGRA, the TT is not recommended<a class="elsevierStyleCrossRef" href="#bib0935">67</a></td><td class="td" title="table-entry " align="left" valign="top">CIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">IGRA should be performed before TT, due to the booster effect detected for IGRAs.<a class="elsevierStyleCrossRefs" href="#bib1035">87,88</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">The specificity and sensitivity of the 2 IGRA techniques for the diagnosis of LTI are similar in patients with IMID; as the sensitivity of T.SPOT.TB is somewhat higher in patients treated with corticosteroids, use of this test should be considered in these patients<a class="elsevierStyleCrossRefs" href="#bib0965">73,74</a></td><td class="td" title="table-entry " align="left" valign="top">BIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Indeterminate results should always be confirmed with a second measurement that, in most cases, is negative<a class="elsevierStyleCrossRefs" href="#bib0955">71,72</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Negativity in the TT and IGRA does not rule out LTI.<a class="elsevierStyleCrossRefs" href="#bib0930">66,66,70,82</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Preventive treatment is recommended in all candidates for therapy who presented with suspicion of LTI, after excluding active TB, in any of the diagnostic tests<a class="elsevierStyleCrossRefs" href="#bib1060">92,93,96,115,116</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Monitoring of treatment should be done monthly. In the case of INH liver toxicity, a 4-month RIF regimen is recommended<a class="elsevierStyleCrossRef" href="#bib1165">113</a> </td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">A period of 4 weeks of treatment for LTI is considered safe (by most experts) for starting treatment with anti-TNF<a class="elsevierStyleCrossRef" href="#bib0905">61</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">The study and screening for LTI, after onset of anti-TNF treatment and during maintenance, as a diagnostic strategy in initial false negatives is not supported by evidence currently available. It is recommended to repeat the screening study if there are changes in clinical symptoms or potential exposure to Mycobacterium tuberculosis due to travel to regions where infection is endemic<a class="elsevierStyleCrossRefs" href="#bib1040">88–91</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">If the patient is diagnosed with active tuberculosis disease, anti-TNF treatment should be suspended; it is recommended to delay reinitiating until the entire TB treatment cycle has been completed. There is no evidence that the duration of treatment for TB disease should be modified in this context<a class="elsevierStyleCrossRef" href="#bib0905">61</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Patients who have correctly completed treatment for TB do not appear to be at a higher risk of relapse when anti-TNF treatment is initiated<a class="elsevierStyleCrossRefs" href="#bib1070">94,95</a></td><td class="td" title="table-entry " align="left" valign="top">AIII \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1838850.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Final Recommendations with Degree of Evidence." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:120 [ 0 => array:3 [ "identificador" => "bib0605" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Tuberculosis global report 2017. World Health Organization [accessed Sep 2017]. Available from: <a id="intr0005" class="elsevierStyleInterRef" href="http://www.who.int/tb">www.who.int/tb</a>" ] ] ] 1 => array:3 [ "identificador" => "bib0610" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: Report of a case series with 144 patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2010.03836.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol." "fecha" => "2011" "volumen" => "25" "paginaInicial" => "730" "paginaFinal" => "733" "link" => array:1 [ …1] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0615" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What can we learn by following the development of tuberculosis from one generation to another? 1930" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Tuberc Lung Dis" "fecha" => "2002" "volumen" => "6" "paginaInicial" => "562" "paginaFinal" => "568" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0620" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A method for estimating the prevalence of tuberculosis infection" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Epidemiol." "fecha" => "1975" "volumen" => "101" "paginaInicial" => "311" "paginaFinal" => "322" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0625" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Infliximab approval process in Crohn's disease. Deparment of Health and Human Services. Public Health Service. Food and Drug Administration; August 24, 1998." ] ] ] 5 => array:3 [ "identificador" => "bib0630" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.123885" "Revista" => array:7 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "numero" => "Suppl I" "paginaInicial" => "i2" "paginaFinal" => "i29" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0635" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa011110" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2001" "volumen" => "345" "paginaInicial" => "1098" "paginaFinal" => "1104" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0640" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.11137" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2003" "volumen" => "48" "paginaInicial" => "2122" "paginaFinal" => "2127" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0645" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.12011" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol." "fecha" => "2012" "volumen" => "27" "paginaInicial" => "1366" "paginaFinal" => "1374" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0650" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab CB Spanish Working Group on Crohn Disease and Ulcerative Colitis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gastroenterol Hepatol" "fecha" => "2003" "volumen" => "26" "paginaInicial" => "29" "paginaFinal" => "33" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0655" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2003" "volumen" => "3" "paginaInicial" => "148" "paginaFinal" => "155" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0660" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.autrev.2015.01.011" "Revista" => array:6 [ "tituloSerie" => "Autoimmun Rev." "fecha" => "2015" "volumen" => "14" "paginaInicial" => "503" "paginaFinal" => "509" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0665" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21043" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2005" "volumen" => "52" "paginaInicial" => "1766" "paginaFinal" => "1772" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0670" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Crohn Colitis." "fecha" => "2013 Apr 1" "volumen" => "7" "paginaInicial" => "208" "paginaFinal" => "212" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0675" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Glucocorticoid use, other associated factors, and the risk of tuberculosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21705" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum." "fecha" => "2006" "volumen" => "55" "paginaInicial" => "19" "paginaFinal" => "26" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0680" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus document on prevention and treatment of tuberculosis in patients for biological treatment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2015.04.016" "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol." "fecha" => "2016" "volumen" => "52" "paginaInicial" => "36" "paginaFinal" => "45" "link" => array:1 [ …1] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0685" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Purpose of quality standards for infectious diseases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis." "fecha" => "1994" "volumen" => "18" "paginaInicial" => "421" "link" => array:1 [ …1] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0690" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "e1-20" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2010.02.006" "Revista" => array:5 [ "tituloSerie" => "Enferm Infecc Microbiol Clin." "fecha" => "2010" "volumen" => "28" "paginaInicial" => "297" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0695" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency. Ficha técnica de Remicade (infliximab) [accessed Sep 2017]. Available from: <a id="intr0010" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf">http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf</a>" ] ] ] 19 => array:3 [ "identificador" => "bib0700" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency. Ficha técnica de Enbrel (etanercept) [accessed Sep 2017]. Available from: <a id="intr0015" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf">http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf</a>" ] ] ] 20 => array:3 [ "identificador" => "bib0705" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency. Ficha técnica de Humira (adalimumab) [accessed Sep 2017]. Available from: <a id="intr0020" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf">http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf</a>" ] ] ] 21 => array:3 [ "identificador" => "bib0710" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency. Ficha técnica de Stelara (ustekinumab) [accessed Sep 2017]. Available from: <a id="intr0025" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf">http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf</a>" ] ] ] 22 => array:3 [ "identificador" => "bib0715" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency. Ficha técnica de Cosentyx (secukinumab) [accessed Sep 2017]. Available from: <a id="intr0030" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003729/WC500183129.pdf">http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003729/WC500183129.pdf</a>" ] ] ] 23 => array:3 [ "identificador" => "bib0720" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency. Ficha técnica de Taltz (ixekizumab) [accessed Sep 2017]. Available from: <a id="intr0035" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf">http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf</a>" ] ] ] 24 => array:3 [ "identificador" => "bib0725" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept for the treatment of psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Expert Rev Dermatol" "fecha" => "2013" "volumen" => "8" "paginaInicial" => "357" "paginaFinal" => "372" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0730" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of infliximab in dermatology" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1610-0387.2007.06319.x" "Revista" => array:6 [ "tituloSerie" => "J Dtsch Dermatol Ges." "fecha" => "2007" "volumen" => "5" "paginaInicial" => "655" "paginaFinal" => "660" "link" => array:1 [ …1] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0735" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The future of biological therapies" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.sder.2010.02.004" "Revista" => array:6 [ "tituloSerie" => "Semin Cutan Med Surg." "fecha" => "2010" "volumen" => "29" "paginaInicial" => "63" "paginaFinal" => "66" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0740" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0051819" "Revista" => array:5 [ "tituloSerie" => "PLoS One." "fecha" => "2012" "volumen" => "7" "paginaInicial" => "e51819" "link" => array:1 [ …1] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0745" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2009.09505.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2009" "volumen" => "161" "paginaInicial" => "987" "paginaFinal" => "1019" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0750" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "e4" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Secukinumab long-term safety experience: A pooled analysis of 10 phase ii and iii clinical studies in patients with moderate to severe plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2016.03.024" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2016" "volumen" => "75" "paginaInicial" => "83" "paginaFinal" => "98" "link" => array:1 [ …1] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0755" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of ixekizumab therapy: Integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Invest Dermatol." "fecha" => "2016" "volumen" => "136" "paginaInicial" => "S170" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0760" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adalimumab for the treatment of moderate to severe hidradenitis suppurativa" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-157-12-201212180-00004" "Revista" => array:5 [ "tituloSerie" => "Ann Intern Med." "fecha" => "2012" "volumen" => "157" "paginaInicial" => "846" "link" => array:1 [ …1] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0765" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brodalumab, an anti–interleukin-17–receptor antibody for Psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Eng J Med." "fecha" => "2012" "volumen" => "366" "paginaInicial" => "1181" "paginaFinal" => "1189" ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0770" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Eng J Med." "fecha" => "2015" "volumen" => "373" "paginaInicial" => "136" "paginaFinal" => "144" ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0775" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.13932" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2015" "volumen" => "173" "paginaInicial" => "930" "paginaFinal" => "939" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0780" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "e12507" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Dermatol Ther." "fecha" => "2017" ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0785" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.12266" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2013" "volumen" => "169" "paginaInicial" => "137" "paginaFinal" => "145" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0790" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tuberculose, agents anti-TNF et autres immunosuppresseurs: Évolution des stratégies de prévention" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Mal Respir" "fecha" => "2008" "volumen" => "25" "paginaInicial" => "1237" "paginaFinal" => "1249" "link" => array:1 [ …1] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0795" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "abstr 356" "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Tuberculosis and etanercept. Proceedings of American College of Rheumatology Conference" "fecha" => "2002 October" ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0800" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Vaccine Immunol." "fecha" => "2008" "volumen" => "155" "paginaInicial" => "506" "paginaFinal" => "512" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0805" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-TNF immunotherapy and tuberculosis reactivation: Another mechanism revealed" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Invest" "fecha" => "2009" "volumen" => "119" "paginaInicial" => "1079" "paginaFinal" => "1082" "link" => array:1 [ …1] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0810" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society of Rheumatology Biologics Register (BSRBR)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.118935" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "522" "paginaFinal" => "528" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0815" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2012.11162.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2012" "volumen" => "168" "paginaInicial" => "444" "paginaFinal" => "446" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0820" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archdermatol.2012.2958" "Revista" => array:5 [ "tituloSerie" => "Arch Dermatol." "fecha" => "2012" "volumen" => "148" "paginaInicial" => "1332" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0825" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "FRI0025 no reactivation of dormant Mycobacterium tuberculosis in human in vitro granuloma model after anti-IL-17A treatment, in contrast to anti-TNF α treatment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis." "fecha" => "2016" "volumen" => "75" …3 ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0830" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of anti-IL-17A, IL-17F and TNF-α antibodies on host resistance to acute Mycobacterium tuberculosis infection in mice" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0835" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Secukinumab treatment shows no evidence for reactivation of previous or latent TB infection in subjects with psoriasis: A pooled phase 3 safety analysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0840" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-TNF immunotherapy reduces CD8 T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1172/JCI38482" "Revista" => array:6 [ …6] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0845" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An antimicrobial activity of cytolytic T cells mediated by granulysin" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0850" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differential effects of cytolytic T cell subsets on intracellular infection" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0855" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "XCLI (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infeciton with Mycobacterium tuberculosis negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1189/jlb.0607426" "Revista" => array:6 [ …6] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0860" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4" "Revista" => array:6 [ …6] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0865" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200503-411OC" "Revista" => array:6 [ …6] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0870" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factors signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.immuni.2008.06.011" "Revista" => array:6 [ …6] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0875" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.20009" "Revista" => array:6 [ …6] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0880" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0885" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21137" "Revista" => array:6 [ …6] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0890" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "TB in patients receiving anti-TNF agents despite chemoprophylaxis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0895" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "TB in the cytokine era: What rheumatologist need to know" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.11134" "Revista" => array:6 [ …6] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0900" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: Diagnostic and therapeutic strategies" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0b013e3283025ec2" "Revista" => array:6 [ …6] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0905" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reinitiation of biologics after the development of tuberculosis under anti-TNF therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0910" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: Safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1469-0691.2007.01891.x" "Revista" => array:6 [ …6] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0915" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Is it safe to readminister tumor necrosis factor α antagonists following tuberculosis flare?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23210" "Revista" => array:6 [ …6] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0920" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Screening for latent tuberculosis in the patient with moderate to severe psoriasis who is a candidate for systemic and/or biologic therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2015.10.004" "Revista" => array:7 [ …7] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0925" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2004.029041" "Revista" => array:6 [ …6] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0930" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of an interferon-γ assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0935" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The tuberculin skin test" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0940" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Cellestis. Quantiferon-TB Gold. 2009 [accessed 20 oct 2009]. Available from: <a id="intr0040" class="elsevierStyleInterRef" href="http://www.cellestis.com/">http://www.cellestis.com/</a>" ] ] ] 68 => array:3 [ "identificador" => "bib0945" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "OxfordImmunotec. T. Spot-TB. 2009 [accessed 20 oct 2009]. Available from: <a id="intr0045" class="elsevierStyleInterRef" href="http://www.oxfordimmunotec.com/">http://www.oxfordimmunotec.com/</a>" ] ] ] 69 => array:3 [ "identificador" => "bib0950" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of two commercially available gamma-interferon blood tests for immunodiagnosis of tuberculosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CVI.00364-07" "Revista" => array:6 [ …6] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0955" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updated guidelines for using interferon g release assays to detect Mycobacterium tuberculosis infection—United States, 2010" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0960" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Centre for Disease Prevention and Control (ECDC). Use of interferon-gamma release assays in support of TB diagnosis [accessed 7 jul 2013]. Available from: <a id="intr0050" class="elsevierStyleInterRef" href="http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf">http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf</a>" ] ] ] 72 => array:3 [ "identificador" => "bib0965" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "e32482" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon-γ release assay for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: A systematic review and metaanalysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0125979" "Revista" => array:3 [ …3] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0970" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Executive summary of the guidelines for the use of interferon-gamma release assays in the diagnosis of tuberculosis infection" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2016.02.020" "Revista" => array:6 [ …6] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0975" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Normativa SEPAR. Diagnóstico y tratamiento de la tuberculosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0980" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of Quantiferon-TB-Gold in Tube® test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2012.06.014" "Revista" => array:6 [ …6] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0985" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of an in vitro tuberculosis interferon-γ assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: A pilot study in rheumatoid arthritis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib0990" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Agreement between Quantiferon-TB Gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.090268" "Revista" => array:6 [ …6] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib0995" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10096-008-0519-1" "Revista" => array:6 [ …6] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib1000" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of Quantiferon TB Gold test as a part of a screening progrmme in patients with RA under consideration for treatment with antiTNF-alpha agents: The Newcastle (UK) experience" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kem064" "Revista" => array:6 [ …6] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib1005" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-007-0361-2" "Revista" => array:6 [ …6] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib1010" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib1015" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2007.070789" "Revista" => array:6 [ …6] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib1020" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib1025" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2007.069799" "Revista" => array:6 [ …6] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib1030" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IFN-gamma release assay to diagnose TB infection in the immunocompromised individual" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/ers.09.20" "Revista" => array:6 [ …6] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib1035" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200811-1704OC" "Revista" => array:6 [ …6] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib1040" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-3083.2008.02103.x" "Revista" => array:6 [ …6] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib1045" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-a inhibitors" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/apt.12037" "Revista" => array:6 [ …6] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib1050" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFa inhibitors: The utility of IFNg assay" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2011-200489" "Revista" => array:6 [ …6] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib1055" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor-alpha antagonists" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/ar3882" "Revista" => array:5 [ …5] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib1060" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221." ] ] ] 92 => array:3 [ "identificador" => "bib1065" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMcp1005750" "Revista" => array:5 [ …5] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib1070" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/arrd.1979.119.5.827" "Revista" => array:5 [ …5] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib1075" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/427802" "Revista" => array:5 [ …5] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib1080" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-- United States, 2003" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib1085" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60:555-564." ] ] ] 97 => array:3 [ "identificador" => "bib1090" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib1095" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Isoniazid therapy for latent tuberculosis in psoriasis patients receiving biological agents: Is it safe and efficacious?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ijd.12127" "Revista" => array:6 [ …6] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib1100" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peripheral neuritis in tuberculous patients treated with isoniazid" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib1105" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "62" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of a shortage of first-line antituberculosis medication on tuberculosis control, United States, 2012-2013" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib1110" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rifampin preventive therapy for tuberculosis infection: Experience with 157 adolescents" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.155.5.9154885" "Revista" => array:5 [ …5] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib1115" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib1120" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.130.6.1712" "Revista" => array:5 [ …5] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib1125" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on rifampin, rifabutin, and rifapentine drug interactions" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1185/03007995.2013.795141" "Revista" => array:6 [ …6] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib1130" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interactions between antiretroviral agents and those used to treat tuberculosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/COH.0b013e3282fbaad0" "Revista" => array:7 [ …7] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib1135" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5588/ijtld.12.0510" "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib1140" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in Southern India: A trial-based analysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0036001" "Revista" => array:5 [ …5] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib1145" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of latent tuberculosis infection in HIV: Shorter or longer?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11904-012-0120-1" "Revista" => array:6 [ …6] ] ] ] ] ] 109 => array:3 [ "identificador" => "bib1150" "etiqueta" => "110" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1055/s-0031-1291619" "Revista" => array:6 [ …6] ] ] ] ] ] 110 => array:3 [ "identificador" => "bib1155" "etiqueta" => "111" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Strategies for treating latent multiple-drug resistant tuberculosis: A decision analysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0030194" "Revista" => array:5 [ …5] ] ] ] ] ] 111 => array:3 [ "identificador" => "bib1160" "etiqueta" => "112" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on tuberculosis: TB in the early 21st century" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00000511" "Revista" => array:6 [ …6] ] ] ] ] ] 112 => array:3 [ "identificador" => "bib1165" "etiqueta" => "113" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of latent tuberculosis infection in HIV infected persons" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 113 => array:3 [ "identificador" => "bib1170" "etiqueta" => "114" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "[Tuberculosis in HIV/AIDS patients] [artículo en japonés]" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 114 => array:3 [ "identificador" => "bib1175" "etiqueta" => "115" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5114/aoms.2013.33352" "Revista" => array:6 [ …6] ] ] ] ] ] 115 => array:3 [ "identificador" => "bib1180" "etiqueta" => "116" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Danish Society for Gastroenterology Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 116 => array:3 [ "identificador" => "bib1185" "etiqueta" => "117" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-γ release assay in patients considered for anti-tumor necrosis factor-α therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.diagmicrobio.2010.12.020" "Revista" => array:6 [ …6] ] ] ] ] ] 117 => array:3 [ "identificador" => "bib1190" "etiqueta" => "118" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: Systematic review" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 118 => array:3 [ "identificador" => "bib1195" "etiqueta" => "119" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "TNF-alpha blockade and tuberculosis: Better look before you leap" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 119 => array:3 [ "identificador" => "bib1200" "etiqueta" => "120" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "You can’t always get what you want, but if you try sometimes (with two tests —TST and IGRA—for tuberculosis) you get what you need" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2012-201979" "Revista" => array:6 [ …6] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018302324/v1_201809020417/en/main.assets" "Apartado" => array:4 [ "identificador" => "23902" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000007/v1_201809020417/S1578219018302324/v1_201809020417/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302324?idApp=UINPBA000044"]

Estadísticas

Special article

Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient

Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico

P. Rodríguez-Jiméneza,

Autor para correspondencia

pedro.rodriguez.jimenez90@gmail.com

Corresponding author.

, I. Mir-Viladrichb, P. Chicharroa, G. Solano-Lópeza, F.J. López-Longoc, C. Taxonerad, P. Sánchez-Martíneze, X. Martínez-Lacasaf, M. García-Gasallag, J. Dorcah, M. Arias-Guilléni, J.M. García-Garcíaj, E. Daudena

a Servicio de Dermatología, IIS-FIB, Hospital Universitario de La Princesa. Madrid, España

b Servicio de Neumología, Hospital Son Llàtzer, Palma de Mallorca, España

c Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España

d Servicio del Aparato Digestivo, Hospital Clínico San Carlos e Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, España

e Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona, España

f Unidad Control de Tuberculosis, Hospital Universitari Mutua de Terrassa, Barcelona, España

g Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Son Llàtzer, Palma de Mallorca, España

h Servicio de Neumología, Hospital Universitario de Bellvitge, Hospitalet de Llobregat (Barcelona), España

i Servicio de Neumología, Hospital Universitario Central de Asturias-Instituto Nacional de Silicosis, Oviedo, España

j Servicio de Neumología, Hospital San Agustín, Avilés, España

Leído

7744

Veces
se ha leído el artículo

2564

Total PDF

5180

Total HTML

Compartir estadísticas

 array:24 [
  "pii" => "S1578219018302324"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2018.06.020"
  "estado" => "S300"
  "fechaPublicacion" => "2018-09-01"
  "aid" => "1954"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
  "copyrightAnyo" => "2018"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2018;109:584-601"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6
    "formatos" => array:2 [
      "HTML" => 1
      "PDF" => 5
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731018301790"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2018.03.013"
      "estado" => "S300"
      "fechaPublicacion" => "2018-09-01"
      "aid" => "1954"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "Actas Dermosifiliogr. 2018;109:584-601"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 1057
        "formatos" => array:3 [
          "EPUB" => 1
          "HTML" => 732
          "PDF" => 324
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">ART&#205;CULO ESPECIAL</span>"
        "titulo" => "Consenso multidisciplinar sobre prevenci&#243;n y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol&#243;gico&#46; Adaptaci&#243;n al paciente dermatol&#243;gico"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "584"
            "paginaFinal" => "601"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Prevention and treatment of tuberculosis infection in candidates for biologic therapy&#58; A multidisciplinary consensus statement adapted to the dermatology patient"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0010"
            "etiqueta" => "Figura 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 2665
                "Ancho" => 2167
                "Tamanyo" => 302244
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">En ausencia de anti-FNT-&#945;&#44; las c&#233;lulas T citot&#243;xicas efectoras de memoria &#40;T<span class="elsevierStyleInf">EMRA</span>&#41; liberan los gr&#225;nulos con enzimas citol&#237;ticas &#40;perforina&#44; granulolisina&#41; que destruyen los macr&#243;fagos infectados por <span class="elsevierStyleItalic">M&#46; tuberculosis</span> as&#237; como los bacilos intra- y extracelulares&#46; En presencia de anti-FNT-&#945;&#44; el FNT transmembrana de los T<span class="elsevierStyleInf">EMRA</span> queda ligado a este anticuerpo&#44; favoreciendo la apoptosis linfocitaria&#46; La depleci&#243;n de linfocitos T citot&#243;xicos impide&#44; por tanto&#44; el control del crecimiento y permite la diseminaci&#243;n de <span class="elsevierStyleItalic">M&#46; tuberculosis</span>&#46;</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Fuente&#58; Adaptado de Miller y Ernst&#46;<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">41</span></a>&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "P&#46; Rodr&#237;guez-Jim&#233;nez, I&#46; Mir-Viladrich, P&#46; Chicharro, G&#46; Solano-L&#243;pez, F&#46;J&#46; L&#243;pez-Longo, C&#46; Taxonera, P&#46; S&#225;nchez-Mart&#237;nez, X&#46; Mart&#237;nez-Lacasa, M&#46; Garc&#237;a-Gasalla, J&#46; Dorca, M&#46; Arias-Guill&#233;n, J&#46;M&#46; Garc&#237;a-Garc&#237;a, E&#46; Dauden"
            "autores" => array:13 [
              0 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Rodr&#237;guez-Jim&#233;nez"
              ]
              1 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Mir-Viladrich"
              ]
              2 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Chicharro"
              ]
              3 => array:2 [
                "nombre" => "G&#46;"
                "apellidos" => "Solano-L&#243;pez"
              ]
              4 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "L&#243;pez-Longo"
              ]
              5 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Taxonera"
              ]
              6 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "S&#225;nchez-Mart&#237;nez"
              ]
              7 => array:2 [
                "nombre" => "X&#46;"
                "apellidos" => "Mart&#237;nez-Lacasa"
              ]
              8 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Garc&#237;a-Gasalla"
              ]
              9 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Dorca"
              ]
              10 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Arias-Guill&#233;n"
              ]
              11 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Garc&#237;a-Garc&#237;a"
              ]
              12 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Dauden"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219018302324"
          "doi" => "10.1016/j.adengl.2018.06.020"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302324?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018301790?idApp=UINPBA000044"
      "url" => "/00017310/0000010900000007/v1_201809020415/S0001731018301790/v1_201809020415/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219018302294"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2018.06.017"
    "estado" => "S300"
    "fechaPublicacion" => "2018-09-01"
    "aid" => "1898"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2018;109:602-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1
      "PDF" => 1
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Practical Dermatology</span>"
      "titulo" => "Allergic Contact Dermatitis Due to Paraphenylenediamine&#58; An Update"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "602"
          "paginaFinal" => "609"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Actualizaci&#243;n en la dermatitis de contacto al&#233;rgica por parafenilendiamina"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0020"
          "etiqueta" => "Figure 4"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr4.jpeg"
              "Alto" => 870
              "Ancho" => 1300
              "Tamanyo" => 96387
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Chronic hyperkeratotic eczema affecting the palm&#44; palmar surface of the fingers&#44; and anterior surface of the wrist in a hairdresser with positive results to paraphenylenediamine and thiuram in patch tests&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "B&#46; Encabo Dur&#225;n, D&#46; Romero-P&#233;rez, J&#46;F&#46; Silvestre Salvador"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "B&#46;"
              "apellidos" => "Encabo Dur&#225;n"
            ]
            1 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "Romero-P&#233;rez"
            ]
            2 => array:2 [
              "nombre" => "J&#46;F&#46;"
              "apellidos" => "Silvestre Salvador"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731018300401"
        "doi" => "10.1016/j.ad.2017.12.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018300401?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302294?idApp=UINPBA000044"
    "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018302294/v1_201809020417/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1578219018301938"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2018.06.001"
    "estado" => "S300"
    "fechaPublicacion" => "2018-09-01"
    "aid" => "1953"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Actas Dermosifiliogr. 2018;109:582-3"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Opinion Article</span>"
      "titulo" => "Ertapenem for the treatment of Hidradenitis suppurativa&#58; how much do we need it&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "582"
          "paginaFinal" => "583"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Ertapenem para el tratamiento de hidradenitis supurativa&#58; &#191;en qu&#233; medida lo necesitamos&#63;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "P&#46; Mendes-Bastos, A&#46; Martorell, S&#46; Magina"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Mendes-Bastos"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Martorell"
            ]
            2 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Magina"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731018301789"
        "doi" => "10.1016/j.ad.2018.03.012"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018301789?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301938?idApp=UINPBA000044"
    "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018301938/v1_201809020417/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>"
    "titulo" => "Prevention and treatment of tuberculosis infection in candidates for biologic therapy&#58; A multidisciplinary consensus statement adapted to the dermatology patient"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "584"
        "paginaFinal" => "601"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "P&#46; Rodr&#237;guez-Jim&#233;nez, I&#46; Mir-Viladrich, P&#46; Chicharro, G&#46; Solano-L&#243;pez, F&#46;J&#46; L&#243;pez-Longo, C&#46; Taxonera, P&#46; S&#225;nchez-Mart&#237;nez, X&#46; Mart&#237;nez-Lacasa, M&#46; Garc&#237;a-Gasalla, J&#46; Dorca, M&#46; Arias-Guill&#233;n, J&#46;M&#46; Garc&#237;a-Garc&#237;a, E&#46; Dauden"
        "autores" => array:13 [
          0 => array:4 [
            "nombre" => "P&#46;"
            "apellidos" => "Rodr&#237;guez-Jim&#233;nez"
            "email" => array:1 [
              0 => "pedro&#46;rodriguez&#46;jimenez90&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Mir-Viladrich"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Chicharro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "G&#46;"
            "apellidos" => "Solano-L&#243;pez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "L&#243;pez-Longo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "C&#46;"
            "apellidos" => "Taxonera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "S&#225;nchez-Mart&#237;nez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "X&#46;"
            "apellidos" => "Mart&#237;nez-Lacasa"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Garc&#237;a-Gasalla"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Dorca"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Arias-Guill&#233;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Garc&#237;a-Garc&#237;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Dauden"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:10 [
          0 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; IIS-FIB&#44; Hospital Universitario de La Princesa&#46; Madrid&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Neumolog&#237;a&#44; Hospital Son Ll&#224;tzer&#44; Palma de Mallorca&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Reumatolog&#237;a&#44; Hospital General Universitario Gregorio Mara&#241;&#243;n&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio del Aparato Digestivo&#44; Hospital Cl&#237;nico San Carlos&#160;e Instituto de Investigaci&#243;n del Hospital Cl&#237;nico San Carlos &#40;IdISSC&#41;&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Enfermedades Infecciosas&#44; Hospital del Mar&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Unidad Control de Tuberculosis&#44; Hospital Universitari Mutua de Terrassa&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Unidad de Enfermedades Infecciosas&#44; Servicio de Medicina Interna&#44; Hospital Son Ll&#224;tzer&#44; Palma de Mallorca&#44; Espa&#241;a"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Servicio de Neumolog&#237;a&#44; Hospital Universitario de Bellvitge&#44; Hospitalet de Llobregat &#40;Barcelona&#41;&#44; Espa&#241;a"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Servicio de Neumolog&#237;a&#44; Hospital Universitario Central de Asturias-Instituto Nacional de Silicosis&#44; Oviedo&#44; Espa&#241;a"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Servicio de Neumolog&#237;a&#44; Hospital San Agust&#237;n&#44; Avil&#233;s&#44; Espa&#241;a"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Consenso multidisciplinar sobre prevenci&#243;n y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol&#243;gico&#46; Adaptaci&#243;n al paciente dermatol&#243;gico"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figure 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1998
            "Ancho" => 2088
            "Tamanyo" => 209567
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Provisional algorithm for assessment of TB infection in candidates for anti-TNF treatment&#46;</p> <p id="spar0060" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">a</span> Appropriate treatment for TB is defined as &#8805;6 months of treatment with first-line drugs&#44; including &#8805;2 months of the combination of rifampicin&#44; isoniazid&#44; pyrazinamide and ethambutol&#46; Appropriate treatment for latent infection can be administration of &#8805;6 months of isoniazid&#44; 3 months of isoniazid and rifampicin&#44; or 4 months of rifampicin alone&#46;</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">b</span> The risk of latent infection is determined by weighting factors such as exposure to known contagious case&#44; age&#44; country of origin&#44; and work and social history of the individual&#44; including travel to endemic countries and repeated exposure to collectives at risk &#40;closed institutions&#44; homeless&#44; drug users&#41;&#46;</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">c</span> In those infected many years earlier&#44; TT can be negative and become positive in a second TT &#40;booster phenomenon&#41;&#46; With the availability of IGRAs&#44; it would seem more practical to use these as complementary tests rather than performing a second TT&#44; both in patients aged more than 60 years and in immunosuppressed patients due to different causes&#44; regardless of age&#46;</p> <p id="spar0075" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">d</span> There are no conclusive data to establish a safe period between the start of treatment for latent infection and the start of anti-TNF therapy&#46; Four weeks delay is considered usual practice and safe by most experts&#46;</p> <p id="spar0080" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">e</span>Active TB treatment should be completed before starting biological therapy&#46; See text for interpretation and extension of this algorithm&#46;</p> <p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Anti-TNF&#44; anti-tumor necrosis factor&#59; BCG&#44; bacillus Calmette-Guerin&#59; IGRA&#44; interferon &#947; release assay&#59; TB&#44; tuberculosis&#59; TT&#44; tuberculin test&#46;</p> <p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Source&#58; Adapted from Winthrop&#46;&#46;<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">120</span></a></p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">According to current estimates&#44; a third of the world population is a carrier of latent <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> infection&#44;<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">1</span></a> which can become reactivated&#44; particularly in immunocompromised patients&#46; The estimated incidence of latent tuberculosis infection &#40;LTI&#41; in Spain in patients with psoriasis treated with anti-tumor necrosis factor &#40;TNF&#41; agents is 29&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">2</span></a> In the best case scenario&#44; only 10&#37; of those infected will develop active tuberculosis &#40;TB&#41; during their lifetimes&#46;<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">3&#44;4</span></a> However&#44; there are factors that may significantly increase this percentage and so latent infection is considered a major obstacle for worldwide elimination of TB&#46; Public health measures and&#44; ultimately&#44; clinical management of TB infection could be improved if we had a better knowledge of latent and reactivated states of <span class="elsevierStyleItalic">M tuberculosis</span>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">On the other hand&#44; in the past 10 years&#44; development of biological therapies as led to a major change in the treatment of some chronic inflammatory skin diseases&#44; and psoriasis in particular&#44; but also hidradenitis suppurativa after the recent approval of adalimumab in that indication&#46; In 1998&#44; the Food and Drug Administration approved the use of infliximab in patients with psoriasis who are refractory to conventional immunomodulatory treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">5</span></a> Since then&#44; more than 20 new drugs have become available for the treatment of immune-mediated inflammatory diseases &#40;IMIDs&#41; in which TNF and its receptors play a key role in acute and chronic inflammatory responses&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">TNF is important for immune response&#44; and so drugs that target this molecule may increase the risk of infections and TB reactivation&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Postmarketing surveillance of the first biological agents to be approved &#40;infliximab and etanercept&#41; soon revealed the appearance of associated cases of TB&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">7</span></a> In Spain&#44; since February 2000&#44; a surveillance program with active data acquisition in the Biological Products Database of the Spanish Rheumatology Society &#40;BIOBADASER&#41;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">8</span></a> has been implemented and in October 2008&#44; the Spanish registry of systemic psoriasis treatments &#40;BIOBADADERM&#41; was set up as part of the pharmacovigilance strategy&#46;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">9</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Evidence from reported cases showed a strong association between infliximab therapy and increased risk of active TB&#46; This soon forced guidelines and recommendations to be established such as the one published in 2003 by the Spanish Work Group for Crohn Disease and Ulcerative Colitis &#40;GETECCU&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">10</span></a> for the prevention of TB in candidates for infliximab treatment&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Diagnosis of LTI and preventive treatment with isoniazid &#40;INH&#41; for 9 months has been established as a means to reduce the probability of progression to active TB&#44;<a class="elsevierStyleCrossRefs" href="#bib0655"><span class="elsevierStyleSup">11&#44;12</span></a> and it has been shown that implementation of LTI screening protocols in candidates for anti-TNF therapy has reduced the incidence of TB by more than 78&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">13</span></a> However&#44; new cases have continued to arise&#44; even after preventive treatment with INH&#44;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">14</span></a> and this has forced the protocols to be updated and attempts to improve the sensitivity and specificity of the diagnostic tests and treatments in this population&#44; with a high risk of progression to active TB&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">15</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Objectives of the Document</span><p id="par0035" class="elsevierStylePara elsevierViewall">The availability of abundant and recent information on new biological therapies and the lack of guidelines agreed among different Spanish scientific societies was the rationale behind the need for a consensus document&#44; published in 2016&#46; This document aimed to collate existing information and recommendations on the basis of evidence available and consensus of a group of experts&#46;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">16</span></a> The objective of the present document is to update and extend the information in the earlier document and adapt it to dermatology patients&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Methodology</span><p id="par0040" class="elsevierStylePara elsevierViewall">The document has been drafted by designated experts from the participating societies &#40;Spanish Academy of Dermatology and Venereology&#44; Spanish Society of Pneumology and Thoracic Surgery&#44; Spanish Society of Digestive Pathology&#44; Spanish Society of Rheumatology&#44; and Spanish Society of Infectious Diseases and Clinical Microbiology&#41; who spend a large part of their time on the study and control of candidates for biological therapies and who have particular experience in this field&#46; The most recent editions of Spanish and international guidelines for biological diseases&#44; diagnosis and treatment of LTI&#44; and databases of Medline and Cochrane up until July 2017 were consulted&#46; With the information obtained&#44; recommendations were established based on the classification of the Infectious Diseases Society of America&#44;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">17</span></a> as well as the strength of the recommendation<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">18</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Biological Treatments Approved in Dermatology</span><p id="par0045" class="elsevierStylePara elsevierViewall">Currently&#44; the biological agents with an indication approved in Spain for psoriasis are infliximab&#44; etanercept&#44; adalimumab&#44; ustekinumab&#44; secukinumab&#44; and ixekizumab&#46;<a class="elsevierStyleCrossRefs" href="#bib0695"><span class="elsevierStyleSup">19&#8211;31</span></a> Adalimumab has also recently been approved for the treatment of hidrosadenitis suppurativa&#46;<a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">32</span></a> There are no other biological agents approved for diseases specifically of the skin&#46; <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> summarizes the main indications for each biological agent and the date of approval in Spain&#46;<a class="elsevierStyleCrossRefs" href="#bib0695"><span class="elsevierStyleSup">19&#8211;24</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">Currently&#44; new therapeutic options are emerging for the treatment of psoriasis such as brodalumab<a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">33</span></a> &#40;IL17 receptor antagonist&#41;&#59; guselkumab&#44;<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">34</span></a> tildrakizumab<a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">35</span></a> and risankizumab<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">36</span></a> &#40;anti-IL23&#41;&#59; and tofacitinib<a class="elsevierStyleCrossRef" href="#bib0785"><span class="elsevierStyleSup">37</span></a> &#40;Janus kinase 1 and 3 inhibitor&#41;&#46; The biological agents currently available have already been shown to be effective in diseases other than psoriasis &#40;sarcoidosis&#44; lipoid necrobiosis&#44; granuloma annulare&#44; pityriasis rubra pilaris&#41;&#44; and some of these may be approved in these indications in the near future&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Tuberculosis and Biological Therapy</span><p id="par0055" class="elsevierStylePara elsevierViewall">Corticosteroid therapy in systemic diseases and immunosuppressant protocols to prevent graft rejection in transplantation have demonstrated in the past that TB is a real problem for patients treated with immunosuppressants<a class="elsevierStyleCrossRef" href="#bib0790"><span class="elsevierStyleSup">38</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46; The development of active TB in this population is a clear cause for concern&#58; diagnosis may be delayed due to an atypical presentation&#44;<a class="elsevierStyleCrossRefs" href="#bib0635"><span class="elsevierStyleSup">7&#44;39</span></a> patients may present with adverse effects due to the underlying diseases or drug interactions&#44; and the potential for TB transmission to the community should not be forgotten&#44; including infection of other immunosuppressed patients who receive similar medical care in shared treatment areas&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">TNF is a potent modulator of early inflammatory response to a large variety of physical&#44; environmental&#44; infectious&#44; and immunological stimuli&#46; Specifically&#44; TNF is a key part of the body&#39;s defense against <span class="elsevierStyleItalic">M tuberculosis</span> and&#44; along with interferon &#40;IFN&#41; &#947; and other related cytokines&#44; it plays an important role in the development and maintenance of granulomas as structures that compartmentalize and contain the tuberculosis bacillus during infection<a class="elsevierStyleCrossRefs" href="#bib0800"><span class="elsevierStyleSup">40&#44;41</span></a> &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; Inhibition of TNF and its regulatory network is the biological basis that appears to explain the 4- to 5-fold increase&#44; on average&#44; in TB incidence in patients with TB infection who receive infliximab&#46;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">8</span></a> Cases of TB have also been reported with other lower affinity TNF inhibitors&#44; such as etanercept&#44; a fusion protein that binds to the soluble portion of the TNF receptor&#44; and adalimumab&#44; a monoclonal antibody like infliximab&#44; but fully human&#46;<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">42</span></a> Only exceptionally&#44; and without a clear causal relationship&#44; has ustekinumab&#44; a p40 protein inhibitor of IL12 and IL23&#44; been related with possible reactivation of latent TB&#46;<a class="elsevierStyleCrossRefs" href="#bib0815"><span class="elsevierStyleSup">43&#44;44</span></a> IL17 inhibition&#44; in contrast&#44; does not appear to reactivate LTI according to in vitro models&#46;<a class="elsevierStyleCrossRefs" href="#bib0825"><span class="elsevierStyleSup">45&#8211;47</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">It is believed that granulomas are the structures that contribute to control of the intramacrophagic bacilli&#44; as they provide a local environment in which antigen presenting cells &#40;APCs&#41; and lymphocytes interact to suppress growth and proliferation&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">7</span></a> A large part of the work for determining the TB reactivation mechanisms has focused on the role of TNF in the formation and maintenance of these structures&#46; Bruns et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">48</span></a> however&#44; described an additional mechanism to explain the susceptibility to TB progression in individuals treated with infliximab&#46; In cells from patients with a positive tuberculin test&#44; they identified a subset of effector T cells&#44; denominated CD8&#43; effector memory T cells &#40;T<span class="elsevierStyleInf">EMRA</span>&#41;&#44; which are memory cells rich in granulysin&#44; a protein with antimycobacterial properties&#44; and they showed that T<span class="elsevierStyleInf">EMRA</span> are selectively depleted by the effect of infliximab in patients with rheumatoid arthritis &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">Cell-based immunity is essential for control of TB infection and&#44; for a long time now&#44; it has been recognized that CD4&#43; T cells are important mediators of <span class="elsevierStyleItalic">M tuberculosis</span> immunity&#46; More recently&#44; the focus has been on specific CD8&#43; cells&#44; but the meaning of this finding has yet to be determined&#44; particularly in humans&#46; It is believed that CD8&#43; cells directly limit growth of mycobacteria by causing death of infected cells&#44;<a class="elsevierStyleCrossRefs" href="#bib0845"><span class="elsevierStyleSup">49&#44;50</span></a> and also indirectly&#44; through release of cytokines that promote activation of macrophages and chemokines that coordinate recruitment of other cells&#46; Other studies indicate that CD8&#43; cells are probably less important during the acute phase of infection by <span class="elsevierStyleItalic">M tuberculosis</span> but essential during the chronic phase&#44; and so they may help prevent TB reactivation&#46;<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">51&#44;52</span></a> On assessment of the contribution of CD8&#43; cells to <span class="elsevierStyleItalic">M tuberculosis</span> immunity&#44; it is important to remember that mice do not express granulysin&#44; the cytolytic protein that&#44; in humans&#44; contributes to the death of <span class="elsevierStyleItalic">M tuberculosis</span>&#46;<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">49</span></a> Thus&#44; studies in murine models may underestimate the importance of the antimycobacterial properties of CD8&#43; cells if their role is to be extrapolated to human immunity&#46; Fewer studies have been performed in humans&#44; but in vitro experiments show that T<span class="elsevierStyleInf">EMRA</span> exhibit a high avidity for stains specific to granulysin and show higher levels both of cytotoxicity and antimycobacterial activity compared with other T cell subsets&#46;<a class="elsevierStyleCrossRef" href="#bib0865"><span class="elsevierStyleSup">53</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">The study by Bruns et al&#46;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">48</span></a> goes beyond the definition of T<span class="elsevierStyleInf">EMRA</span> as mere effectors with potential antimycobacterial importance&#44; and attempts to explain the consequences of TNF blockade on these cells based on observations of <span class="elsevierStyleItalic">M tuberculosis</span> growth in cell culture&#46; With these observations&#44; an apparently new mechanism is described in which TNF is neutralized&#44; thereby facilitating progression of latent infection to active infection&#46; Previous studies in animal models had shown variable increases in bacillary load in absence of TNF&#46;<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">54</span></a> The results of these studies indicated that TNF contributes to direct control of intramacrophagic mycobacteria and indirect suppression of mycobacterial growth by modulating the formation and persistence of granulomas&#46;</p><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Risk of Tuberculosis With Anti-TNF Agents</span><p id="par0080" class="elsevierStylePara elsevierViewall">TB infection is caused&#44; in general&#44; by inhalation of viable bacilli that usually persist in an inactive state known as LTI&#44; although occasionally they can progress rapidly leading to active disease&#46; Individuals with LTI remain asymptomatic and are not contagious&#46; In most cases&#44; initial infection by <span class="elsevierStyleItalic">M tuberculosis</span> can be contained by the hosts own defenses and the infection remains latent&#46; However&#44; this situation of latent infection can quickly turn into a disease state at any time&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">The risk of TB reactivation with use of anti-TNF agents depends on 2 variables&#58; the immunomodulatory effect of treatment and the underlying prevalence of TB infection&#44; or of individuals at risk of infection in a given population&#46; <a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a> presents incidence data published in the first 10 years of use of anti-TNF agents for treatment of rheumatoid arthritis&#59; note&#44; however&#44; that the results cannot necessarily be applied to dermatology patients&#46;<a class="elsevierStyleCrossRefs" href="#bib0790"><span class="elsevierStyleSup">38&#44;55&#8211;57</span></a></p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">Previous treatment for latent infection does not mean the patient is fully protected&#44;<a class="elsevierStyleCrossRef" href="#bib0890"><span class="elsevierStyleSup">58</span></a> and no standard period has been established for reactivation&#59; rather&#44; this may vary according to the drug used&#46;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">59</span></a> The Italian multidisciplinary group for the detection of TB in patients receiving biological therapy &#40;SAFEBIO&#41; concluded in their guidelines that etanercept&#44; among all anti-TNF agents&#44; is the one with lowest risk of reactivation of LTI&#46;<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">12</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Moreover&#44; there is evidence that exposure to more than 1 anti-TNF drug may double the relative risk of exposure to a single drug for development of serious infections&#46;<a class="elsevierStyleCrossRef" href="#bib0900"><span class="elsevierStyleSup">60</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Reinitiating Biological Treatment After Reactivation of Tuberculosis</span><p id="par0100" class="elsevierStylePara elsevierViewall">In the cohort study by Ozguler et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">61</span></a> of 2754 patients treated with biological agents identified&#44; 22 cases of active TB during treatment were identified&#46; One of these patients with active disease died within a month due to miliary TB&#46; In 16 of the 21 remaining patients &#40;76&#37;&#41;&#44; after initial suspension of treatment&#44; biological therapy was restarted&#58; etanercept in 6 cases and rituximab in 5 cases were the most extensively used drugs&#46; Of patients who restarted therapy&#44; treatment was reinitiated while anti-TB therapy was ongoing in 4 patients&#44; while 12 reinitiated after the course of anti-TB therapy&#46; The median duration of follow-up after restarting treatment was 53 months &#40;range 40-75 months&#41;&#46; Only 1 of the patients who had restarted biological treatment presented with a second reactivation&#46; This was satisfactorily treated with anti-TB therapy&#59; subsequent follow-up of 33 months of biological maintenance therapy did not identify any further reactivation of infection&#46; The authors concluded that restarting treatment with anti-TNF drugs&#44; even during TB treatment&#44; appears to be a viable option in patients who have previously developed TB infection during treatment with anti-TNF agents&#44; although careful follow-up and monitoring are required&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">The French RATIO group published the results of follow-up of 21 patients who had developed TB while receiving anti-TNF therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0910"><span class="elsevierStyleSup">62</span></a> In 4 patients&#44; it was necessary to restart biological therapy &#40;in 3 of them during anti-TB treatment&#41; and there was no recurrence of infection after a mean follow-up of 42&#46;7 months&#46; Aislandis et al&#46;<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">63</span></a> published a series of 5 patients with rheumatoid arthritis who had developed TB during anti-TNF therapy&#46; In 3 of these&#44; biological therapy had to be restarted&#44; in all cases after completing anti-TB treatment&#44; and there was no recurrence of infection after a mean follow-up of 24 months&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Therefore&#44; it seems possible to restart biological therapy in cases of TB reactivation with an appropriate safety margin with respect to start of TB therapy&#46;</p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Diagnostic Techniques for Latent Tuberculosis Infection</span><p id="par0115" class="elsevierStylePara elsevierViewall">Investigation of possible TB infection in candidates for biological treatment should start with evaluation of the potential risk of exposure to <span class="elsevierStyleItalic">M tuberculosis</span>&#46; The highest-risk groups are summarized in <a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">In absence of a gold standard for diagnosis of TB infection&#44; current management of patients with autoimmune diseases who are candidates for anti-TNF treatment includes a directed medical history to investigate history of TB or latent infection&#44; whether treated or not&#59; assessment of the risk of exposure to possible active cases&#59; the search for evidence of prior TB in the chest x-ray&#59; and tests to detect LTI &#40;tuberculin test &#91;TT&#93; or interferon-&#947; release assay &#91;IGRA&#93;&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0920"><span class="elsevierStyleSup">64</span></a></p><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Tuberculin Test</span><p id="par0125" class="elsevierStylePara elsevierViewall">TT is a measure of delayed hypersensitivity response to intradermal inoculation with a purified protein derivative&#44; a mixture of more than 200 proteins from <span class="elsevierStyleItalic">M tuberculosis</span>&#46; Given that the antigens contained in the purified protein derivative are also present in other mycobacteria&#44; bacillus Calmette and Guerin &#40;BCG&#41; vaccination may also lead to false positives&#46; Moreover&#44; TT sensitivity is compromised in patients receiving immunosuppressive treatment&#44; with a high rate of false negatives&#46;<a class="elsevierStyleCrossRef" href="#bib0925"><span class="elsevierStyleSup">65</span></a> Studies in patients with rheumatoid arthritis have shown that the rate of TT false negatives can be as high as 40&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0930"><span class="elsevierStyleSup">66</span></a> At times&#44; repetition of the TT may be indicated to increase its sensitivity due to the booster effect on false negatives&#44; but this also reduces its specificity&#44; as it increases the number of false positives due to BCG vaccination and exposure to non-TB mycobacteria&#46;<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">67</span></a> Logistical drawbacks&#44; including the need for a visit for the readout&#44; and observer subjectivity on recording the result of the test may also impact its efficiency&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">According to some authors&#44; given that almost all candidates for anti-TNF treatment are receiving &#40;or have received&#41; another immunosuppressive agent&#44; TT would not be the ideal test for LTI screening in patients with inflammatory diseases&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">7</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">The TT should never be repeated in patients with a positive result&#44; as it will continue to be positive in most cases&#46; There is a potential risk of severe reactions on repetition of the test while no clinical benefit is expected&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Tests Based on Interferon &#947; Release Assay</span><p id="par0140" class="elsevierStylePara elsevierViewall">Sequencing of the <span class="elsevierStyleItalic">M tuberculosis</span> genome enabled better identification of the genes involved in its pathogenesis and awareness of the presence of regions of differing genetics&#46; In the region known as RD1&#44; proteins specific to <span class="elsevierStyleItalic">M tuberculosis</span> are secreted &#40;ESAT-6 and CFP-10&#41;&#46; These proteins act as specific antigens&#44; inducing a Th1 type immune response with IFN-&#947; production in patients with <span class="elsevierStyleItalic">M tuberculosis</span> infection&#46; This region&#44; absent in all strains of <span class="elsevierStyleItalic">Mycobacterium bovis-BCG</span> and in almost all non-TB mycobacteria&#44; except for <span class="elsevierStyleItalic">Mycobacterium kansasii</span>&#44; <span class="elsevierStyleItalic">Mycobacterium marinum</span>&#44; and <span class="elsevierStyleItalic">Mycobacterium szulgai</span>&#44; is present in all known virulent strains of <span class="elsevierStyleItalic">M&#160;tuberculosis</span>&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">IGRA techniques are therefore based on detection&#44; in peripheral blood of infected individuals&#44; of IFN-&#947; released by sensitized T cells in response to in vitro stimulation with <span class="elsevierStyleItalic">M tuberculosis</span> specific antigens&#46; Two IGRA kits are currently available&#46;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0150" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">QuantiFERON&#174;-TB-Gold in tube</span> &#40;Cellestis Ltd&#46;&#44; Carnegie&#44; Australia&#41;<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">68</span></a> determines the total production of IFN-&#947; in infected individuals using an ELISA technique&#46; A value of 0&#46;35 IU&#47;mL is considered positive&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0155" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">T-SPOT&#46;TB&#174;</span> &#40;Oxford Immunotec Ltd&#46;&#44; UK&#41;<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">69</span></a> was developed by Lalvani at the end of the 1990s&#46; The procedure for this kit is more laborious and requires prior separation of monocyte cells before incubation with ESAT-6 and CFP-10 antigens&#46; The reading is done by the Elispot technique&#44; in which each visible spot represents an IFN-&#947; secreting T cell&#46; The result is considered positive if more than 6 spots are present&#46;</p></li></ul></p><p id="par0160" class="elsevierStylePara elsevierViewall">Both techniques incorporate positive and negative controls able to detect false results due to anergy and immunological problems &#40;reported as indeterminate results&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">70</span></a> In most guidelines&#44; indeterminate results&#44; which occur more frequently in patients with IMID&#44; should be repeated and these are often confirmed as negative&#46;<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">71&#44;72</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">The use of IGRA has a series of advantages over TT&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">1&#46;</span><p id="par0170" class="elsevierStylePara elsevierViewall">Subjectivity in the interpretation of the results is avoided&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">2&#46;</span><p id="par0175" class="elsevierStylePara elsevierViewall">The assay can be repeated if necessary&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">3&#46;</span><p id="par0180" class="elsevierStylePara elsevierViewall">A reading visit at 48-72<span class="elsevierStyleHsp" style=""></span>hours is not needed to obtain the result&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">4&#46;</span><p id="par0185" class="elsevierStylePara elsevierViewall">Standardization and laboratory application are easy&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">5&#46;</span><p id="par0190" class="elsevierStylePara elsevierViewall">Positive controls can be included when anergic patients are detected&#46;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">6&#46;</span><p id="par0195" class="elsevierStylePara elsevierViewall">The patient&#39;s privacy is respected&#46;</p></li></ul></p><p id="par0200" class="elsevierStylePara elsevierViewall">Among the drawbacks&#44; the most important is the cost&#44; which is higher than for the TT&#46; To reduce costs&#44; depending on the capacity of the laboratory&#44; assays can be delayed a reasonable time to enable batch analysis of as many samples as possible at the same time&#46; In any case&#44; implantation of this technique represents a diagnostic improvement and can spare health resources&#46; Its greater specificity decreases the number of false positives compared with TT and&#44; therefore&#44; the costs derived from X-rays&#44; visits&#44; and unnecessary treatment for TB infection&#46; On the other hand&#44; it appears to be more sensitive than TT in those individuals with altered cell immunity at greatest risk of developing TB&#46;<a class="elsevierStyleCrossRefs" href="#bib0965"><span class="elsevierStyleSup">73&#44;74</span></a></p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Interpretation of the Results in Candidates for Biological Treatments</span><p id="par0205" class="elsevierStylePara elsevierViewall">IGRAs are used as routine tests for diagnosis of latent infection in the United States of America&#44; Canada&#44; Australia&#44; Japan&#44; and some western European countries &#40;United Kingdom&#44; Italy&#44; Germany&#44; and Switzerland&#41;&#46; Some countries use them instead of the TT&#44; whereas others use them in combination&#46; In Spain&#44; it is recommended to complement the TT with IGRA to rule out false positives in candidates for chemoprophylaxis with prior BCG vaccination &#40;to rule out false positives to tuberculin&#41; and in those with a negative skin patch test and suspected immunosuppression &#40;to rule out a false negative TT&#41;<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">75</span></a> &#40;<a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>&#41;&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0210" class="elsevierStylePara elsevierViewall">Although numerous articles have been published in recent years&#44; data on the performance of these tests are limited and contradictory&#46;<a class="elsevierStyleCrossRefs" href="#bib0970"><span class="elsevierStyleSup">74&#8211;80</span></a> The data from those studies enable the conclusion that&#58; a&#41; agreement between TT and IGRA is weaker in patients with systemic inflammatory diseases than in healthy subjects due to the lower prevalence of positive TT in the first group<a class="elsevierStyleCrossRefs" href="#bib0930"><span class="elsevierStyleSup">66&#44;81&#8211;86</span></a>&#59; b&#41; the extent of tuberculin response is significantly lower in patients than in healthy controls<a class="elsevierStyleCrossRef" href="#bib0930"><span class="elsevierStyleSup">66</span></a>&#59; c&#41; discordance between TT&#43; and IGRA- is observed in vaccinated patients&#59; d&#41; discordance between TT- and IGRA&#43; is often observed in patients receiving corticosteroid therapy<a class="elsevierStyleCrossRef" href="#bib1030"><span class="elsevierStyleSup">86</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><p id="par0215" class="elsevierStylePara elsevierViewall">Due to the vulnerability of these patients to TB when they are receiving anti-TNF treatment&#44; it seems prudent to perform the 2 tests &#40;TT and IGRA&#41; in parallel to maximize diagnostic sensitivity of screening&#44; at least&#44; until evidence of the utility of IGRA in this population has been consolidated&#46; It is important to mention that when the 2 tests are performed sequentially&#44; IGRAs should be performed first due to the booster effect of the TT&#46;<a class="elsevierStyleCrossRefs" href="#bib1035"><span class="elsevierStyleSup">87&#44;88</span></a> It is not known how long the booster effect persists and whether it depends on the quantity of purified protein derivative administered or its characteristics&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">Given that some patients with latent infection may have false negatives for IGRAs and true positives for TT&#44; and vice versa&#44; the dual screening strategy would enable clinicians to offer preventive treatment to all patients with latent infection &#40;<a class="elsevierStyleCrossRef" href="#tbl0035">Table 7</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><p id="par0225" class="elsevierStylePara elsevierViewall">The results of the IGRAs in patients who are in treatment with anti-TNF agents remain difficult to interpret&#46; One proposed strategy was to repeat the tests after starting biological therapy to detect false negatives&#46; The available data from recent studies<a class="elsevierStyleCrossRefs" href="#bib1045"><span class="elsevierStyleSup">89&#8211;91</span></a> show conversions and reversions in both tests related to reproducibility problems and changes in the patients¿ immune status&#46; Given this variability&#44; it is not recommended to repeat the test for follow-up of patients during treatment&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Treatment of Latent Tuberculosis Infection</span><p id="par0230" class="elsevierStylePara elsevierViewall">The identification and treatment of LTI greatly reduces the risk of reactivation and&#44; thus&#44; has the potential to protect the health of infected individuals as well as preventing further infection by reducing the number of possible sources of contagion&#46;<a class="elsevierStyleCrossRefs" href="#bib1060"><span class="elsevierStyleSup">92&#44;93</span></a></p><p id="par0235" class="elsevierStylePara elsevierViewall">After treatment of LTI&#44; the durability of protection against reactivation is variable and depends on the prevalence of TB in the area and the risk of re-exposure&#46; It is assumed that treatment for LTI can confer lifelong protection against disease&#46; Among Eskimos in Alaska&#44; for example&#44; the protective effect of isoniazid &#40;INH&#41; has been shown to last more than 20 years&#46;<a class="elsevierStyleCrossRefs" href="#bib1070"><span class="elsevierStyleSup">94&#44;95</span></a></p><p id="par0240" class="elsevierStylePara elsevierViewall">The treatment of latent infection is only started once active TB has been excluded&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">Regimens for LTI treatment include INH for 9 months&#44; rifampicin &#40;RIF&#41; monotherapy for 4 months&#44; or INH with RIF for 3 months&#46;<a class="elsevierStyleCrossRef" href="#bib1080"><span class="elsevierStyleSup">96</span></a></p><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Isoniazid for 9 Months</span><p id="par0250" class="elsevierStylePara elsevierViewall">The INH dose used is 5<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d with a maximum of 300<span class="elsevierStyleHsp" style=""></span>mg&#47;d in adults&#46; In children under 16 years of age&#44; the dose used should be 10<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d&#46; The efficacy of INH for reducing the incidence of active TB &#40;compared with placebo&#41; is between 60&#37; and 90&#37;&#46; However&#44; given that not all patients complete the treatment course&#44; the efficacy of treatment is only approximately 60&#37; on average&#46;<a class="elsevierStyleCrossRef" href="#bib1070"><span class="elsevierStyleSup">94</span></a></p><p id="par0255" class="elsevierStylePara elsevierViewall">The only study that compares the efficacy of different durations of INH treatment showed efficacy was 65&#37; for the 6 month regimen and 75&#37; for the 12 month regimen &#40;although the difference was not statistically significant&#41;&#46; By extrapolation of the data from randomized trials&#44; the optimum duration of INH treatment for LTI was considered to be 9 months&#44; as the study showed similar efficacy values from 9 months onwards&#46;<a class="elsevierStyleCrossRefs" href="#bib1070"><span class="elsevierStyleSup">94&#44;97</span></a></p><p id="par0260" class="elsevierStylePara elsevierViewall">The most important side effect of INH is hepatitis&#44; with an incidence of 8&#37;&#46; Most cases are asymptomatic and associated with slight liver enzyme elevations that do not usually exceed 10 times the upper limit of normal&#46;<a class="elsevierStyleCrossRefs" href="#bib1090"><span class="elsevierStyleSup">98&#44;99</span></a> The most important risk factor for development of INH-induced hepatitis is alcohol consumption&#46; Patients should be advised to abstain from alcohol consumption while they are taking INH&#46; Peripheral neuropathy presents in up to 2&#37; of patients who take INH&#46;<a class="elsevierStyleCrossRef" href="#bib1100"><span class="elsevierStyleSup">100</span></a> This is caused by interference in pyridoxine metabolism and can be prevented by pyridoxine supplements &#40;25 and 50<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#41;&#46; This is particularly important for patients with conditions that may predispose them to neuropathy &#40;including diabetes&#44; uremia&#44; alcohol abuse&#44; malnutrition&#44; human immunodeficiency virus infection&#41; as well as pregnant patients with a prior history of convulsions&#46; Pyridoxine should also be administered to babies of breast-feeding mothers who receive INH&#46; Spain has INH formulations that already include vitamin B<span class="elsevierStyleInf">6</span>&#44; and so this problem is minimized&#46;</p><p id="par0265" class="elsevierStylePara elsevierViewall">The preferred treatment regimen for most individuals with LTI is INH daily for 9 months&#44; as recommended by the Centers for Disease Control &#40;CDC&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib1060"><span class="elsevierStyleSup">92&#44;101</span></a> A 6-month course of INH also provides substantial protection&#46; In the context of adherence concerns&#44; clinicians may opt to concentrate their efforts in guaranteeing 6 months of therapy&#46; However&#44; regimens shorter than 9 months are not recommended for children or for patients with fibrotic lesions in chest X-ray or in immunosuppressed patients&#46; For patients with poor adherence to treatment&#44; directly observed therapy may be the preferred approach&#44; with administration once or twice a week&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Rifampicin for 4 Months</span><p id="par0270" class="elsevierStylePara elsevierViewall">The usual dose is 10<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d with a maximum of 600<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#46; The efficacy of RIF for reducing the incidence of active TB is estimated to be similar to INH&#46;<a class="elsevierStyleCrossRefs" href="#bib1110"><span class="elsevierStyleSup">102&#44;103</span></a> Although data are limited&#44; RIF appears to be well-tolerated&#44; with a low rate of hepatotoxicity&#46;<a class="elsevierStyleCrossRef" href="#bib1110"><span class="elsevierStyleSup">102</span></a> The drawbacks to routine adoption of RIF for the treatment of latent TB infection include the possibility of underdiagnosing cases of active TB that could then relapse with strains resistant to RIF&#46; Although this could also occur in cases treated with INH&#44; surprisingly&#44; the incidence of relapse with INH has been very low&#46;<a class="elsevierStyleCrossRef" href="#bib1120"><span class="elsevierStyleSup">104</span></a> Interactions with other drugs and its elevated price have also been factors for concern in the case of RIF&#46; Thus&#44; there are important and potentially prolonged interactions with other drugs&#44; including warfarin&#44; oral contraceptives&#44; certain antihypertensive agents&#44; antiarrhythmic agents&#44; antidepressants and anticonvulsants&#44; methadone&#44; and the protease inhibitor class of antiretrovirals&#46;<a class="elsevierStyleCrossRefs" href="#bib1125"><span class="elsevierStyleSup">105&#44;106</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Isoniazid and Rifampicin for 3 Months</span><p id="par0275" class="elsevierStylePara elsevierViewall">Data on the use of INH and RIF together are limited&#44; but some studies have shown that the combination is an effective regimen with good adherence and well tolerated&#46;<a class="elsevierStyleCrossRef" href="#bib1135"><span class="elsevierStyleSup">107</span></a> A meta-analysis of small studies showed that it is just as effective and no more toxic than the 9-month regimen with INH&#46;<a class="elsevierStyleCrossRef" href="#bib1140"><span class="elsevierStyleSup">108</span></a> In a prospective&#44; randomized study in individuals infected by the human immunodeficiency virus&#44; a regimen of 3 months of INH and RIF daily offered 60&#37; protection&#46;<a class="elsevierStyleCrossRef" href="#bib1145"><span class="elsevierStyleSup">109</span></a></p><p id="par0280" class="elsevierStylePara elsevierViewall">Finally&#44; the combination of RIF with pyrazinamide should not be used for the treatment of ILT&#44; due to the possibility of severe hepatotoxicity&#46;<a class="elsevierStyleCrossRef" href="#bib1080"><span class="elsevierStyleSup">96</span></a></p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Treatment of Latent Tuberculosis Infection in Multidrug Resistant Strains</span><p id="par0285" class="elsevierStylePara elsevierViewall">For exposed patients who supposedly are infected with mycobacteria resistant to multiple agents&#44; treatment of LTI should be individualized&#44; based on the susceptibility profile of the index case&#46;<a class="elsevierStyleCrossRefs" href="#bib1150"><span class="elsevierStyleSup">110&#44;111</span></a> Two drugs should always be chosen to which the organism is susceptible&#44; for example&#44; a combination of pyrazinamide and ethambutol or a fluoroquinolone with antituberculous activity &#40;such as levofloxacin&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib1160"><span class="elsevierStyleSup">112</span></a> The duration of treatment has not been defined&#44; although from 6 to 12 months seems to be the most reasonable&#46; Patients with LTI due to multidrug resistant strains should receive carefully monitored treatment and be followed closely due to the risk of liver toxicity&#46; In the case of extreme multidrug-resistant strains&#44; with resistance to several drugs&#44; prophylaxis in contacts may be very difficult and no regimens have been tested beyond the first-line drugs&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Monitoring of Treatment for Latent Tuberculosis Infection</span><p id="par0290" class="elsevierStylePara elsevierViewall">Patients in treatment for LTI should be supervised monthly with clinical examination and liver testing&#46; Patients should also be educated about the symptoms of hepatitis and instructed to suspend treatment and seek medical attention quickly to reduce the risk of progression to serious disease&#46;<a class="elsevierStyleCrossRef" href="#bib1165"><span class="elsevierStyleSup">113</span></a></p><p id="par0295" class="elsevierStylePara elsevierViewall">Treatment of LTI should be discontinued in symptomatic patients with serum transaminase levels in excess of 3 times the upper limit of normal or in asymptomatic patients with serum transaminase levels more than 5 times the upper limit of normal&#46; Treatment should not be restarted under any circumstances&#46;</p><p id="par0300" class="elsevierStylePara elsevierViewall">A common dilemma is whether to continue LTI treatment after having started complete treatment for suspicion of active TB which is finally not confirmed &#40;negative cultures or histology&#41;&#46; The duration of combination therapy in the initial phase administered may apply to the total duration of treatment for LTI&#46; Subsequent options include interrupting treatment if RIF and pyrazinamide have been given for less than 2 months&#44; continuing treatment with RIF for a total of 4 months &#40;with or without INH&#41;&#44; or continuing with INH treatment for a total of 9 months&#46;<a class="elsevierStyleCrossRef" href="#bib1170"><span class="elsevierStyleSup">114</span></a></p><p id="par0305" class="elsevierStylePara elsevierViewall">In the case of regimens with INH &#40;9 or 6 months&#41;&#44; treatment can be restarted where it was left off if less than 3 months have been lost&#46; Treatment for LTI should be reinitiated from the start if more than 3 months have elapsed&#46; For treatment of LTI with regimens of 3 or 4 months&#44; treatment can be restarted from where it left off if less than 2 months of the course remain&#46;</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Treatment of Latent Tuberculosis Infection in Candidates for Biological Therapies</span><p id="par0310" class="elsevierStylePara elsevierViewall">The CDC recommends treatment of LTI of all patients who are planning to take a TNF inhibitor and who have a positive TT result &#40;induration &#8805;5<span class="elsevierStyleHsp" style=""></span>mm&#41; or a positive IGRA result<a class="elsevierStyleCrossRefs" href="#bib1175"><span class="elsevierStyleSup">115&#44;116</span></a> and in the case of patients with negative TT or IGRA but with evidence of previous TB disease in the chest X-ray &#40;for example&#44; regional fibrosis with or without enlarged hilar lymph nodes&#41; or if there is epidemiological evidence of prior exposure to TB &#40;for example&#44; after having been in close contact with a TB case&#41;&#46;</p><p id="par0315" class="elsevierStylePara elsevierViewall">Patients who are candidates to receive anti-TNF agents with an indication for LTI treatment in general should receive standard therapy&#44; that is&#44; INH for 9 months&#46; The recommendation about what the duration of therapy for LTI should be before starting anti-TNF has not been established&#44; but most authors propose that patients should receive at least 1 month of treatment for LTI before starting anti-TNF therapy&#44; whenever this is possible&#46;<a class="elsevierStyleCrossRefs" href="#bib0670"><span class="elsevierStyleSup">14&#44;117</span></a></p><p id="par0320" class="elsevierStylePara elsevierViewall">Treatment with LTI will not protect against TB in the case of recently acquired infection except&#44; perhaps&#44; during the time that the treatment is administered&#46; Therefore&#44; patients who take anti-TNF agents should avoid exposure to TB &#40;for example&#44; occupational exposure such as in health centers with a high prevalence of TB&#44; homeless shelters&#44; prisons&#44; travel to regions with a high prevalence of TB&#41;&#46; Treatment with INH of latent infection will likewise not protect against reactivation of the infection by INH-resistant strains&#46;<a class="elsevierStyleCrossRef" href="#bib1190"><span class="elsevierStyleSup">118</span></a> There are no studies to enable recommendation of combined regimens of LTI treatment in these patients&#44; although the RIF plus INH regimen has been used by expert groups in a large number of patients&#44; without having detected cases of active TB after starting treatment&#46;</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Recommendations of the Consensus Document</span><p id="par0325" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0040">Table 8</a> summarizes the recommendations of the panel of experts from the scientific societies participating in this multidisciplinary consensus document&#46; The aim is to guide dermatology specialists in the assessment of risk of developing TB and to prevent disease through the diagnosis and treatment of LTI&#46;</p><elsevierMultimedia ident="tbl0040"></elsevierMultimedia><p id="par0330" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#fig0020">Figure 4</a> shows the algorithm proposed for assessment of TB infection in candidates for biological therapy&#46;<a class="elsevierStyleCrossRefs" href="#bib1195"><span class="elsevierStyleSup">119&#44;120</span></a></p><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflicts of Interest</span><p id="par0335" class="elsevierStylePara elsevierViewall">Esteban Daud&#233;n declares he is a member of advisory boards&#44; consultant&#44; grant recipient&#44; research support recipient&#44; participant as an investigator in clinical trials&#44; and recipient of fees for talks with the following pharmaceutical companies&#58; Abbvie &#40;Abbott&#41;&#44; Amgen&#44; Janssen-Cilag&#44; Leo Pharma&#44; MSD&#44; Pfizer&#44; Novartis&#44; Celgene&#44; and Lilly&#46;</p><p id="par0340" class="elsevierStylePara elsevierViewall">Carlos Taxonara Samso declares he is a consultant and speaker for MSD&#44; AbbVie&#44; Jannsen&#44; Takeda&#44; and Pfizer&#46;</p><p id="par0345" class="elsevierStylePara elsevierViewall">Francisco Javier L&#243;pez Longo declares having been an occasional speaker for Abbvie&#44; Actelion&#44; Bristol-Myers-Squibb&#44; GSK&#44; MSD&#44; Pfizer&#44; Roche Farma&#44; and UCB and having received research funding from Abbvie and GSK&#46;</p><p id="par0350" class="elsevierStylePara elsevierViewall">The remaining authors declare that they have no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:18 [
        0 => array:3 [
          "identificador" => "xres1077270"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1023294"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1077269"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1023295"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Objectives of the Document"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Methodology"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Biological Treatments Approved in Dermatology"
        ]
        8 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Tuberculosis and Biological Therapy"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Risk of Tuberculosis With Anti-TNF Agents"
            ]
            1 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Reinitiating Biological Treatment After Reactivation of Tuberculosis"
            ]
          ]
        ]
        9 => array:3 [
          "identificador" => "sec0040"
          "titulo" => "Diagnostic Techniques for Latent Tuberculosis Infection"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Tuberculin Test"
            ]
            1 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Tests Based on Interferon &#947; Release Assay"
            ]
          ]
        ]
        10 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Interpretation of the Results in Candidates for Biological Treatments"
        ]
        11 => array:3 [
          "identificador" => "sec0060"
          "titulo" => "Treatment of Latent Tuberculosis Infection"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Isoniazid for 9 Months"
            ]
            1 => array:2 [
              "identificador" => "sec0070"
              "titulo" => "Rifampicin for 4 Months"
            ]
            2 => array:2 [
              "identificador" => "sec0075"
              "titulo" => "Isoniazid and Rifampicin for 3 Months"
            ]
          ]
        ]
        12 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Treatment of Latent Tuberculosis Infection in Multidrug Resistant Strains"
        ]
        13 => array:2 [
          "identificador" => "sec0085"
          "titulo" => "Monitoring of Treatment for Latent Tuberculosis Infection"
        ]
        14 => array:2 [
          "identificador" => "sec0090"
          "titulo" => "Treatment of Latent Tuberculosis Infection in Candidates for Biological Therapies"
        ]
        15 => array:2 [
          "identificador" => "sec0095"
          "titulo" => "Recommendations of the Consensus Document"
        ]
        16 => array:2 [
          "identificador" => "sec0100"
          "titulo" => "Conflicts of Interest"
        ]
        17 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2017-11-04"
    "fechaAceptado" => "2018-03-19"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1023294"
          "palabras" => array:5 [
            0 => "Psoriasis"
            1 => "Hidradenitis suppurativa"
            2 => "Biologic therapy"
            3 => "Tuberculosis"
            4 => "Consensus"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1023295"
          "palabras" => array:5 [
            0 => "Psoriasis"
            1 => "Hidrosadenitis supurativa"
            2 => "Terapias biol&#243;gicas"
            3 => "Tuberculosis"
            4 => "Consenso"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Patients with chronic inflammatory diseases being treated with immunosuppressive drugs&#44; and with tumor necrosis factor inhibitors in particular&#44; have an increased risk of infection by <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span>&#46; Screening for latent tuberculosis infection and preventive therapy to reduce the risk of progression to active tuberculosis are mandatory in this group of patients&#46; This updated multidisciplinary consensus document presents the latest expert opinions on the treatment and prevention of tuberculosis in candidates for biologic therapy and establishes recommendations based on current knowledge relating to the use of biologic agents&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">El riesgo de infecci&#243;n por <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> se halla aumentado en los pacientes con enfermedades inflamatorias cr&#243;nicas y en tratamiento inmunosupresor&#44; en particular con terapia antifactor de necrosis tumoral &#945;&#46; La detecci&#243;n de la infecci&#243;n tuberculosa latente y el tratamiento preventivo dirigido a reducir el riesgo de progresi&#243;n a tuberculosis activa es obligatoria en este grupo de pacientes&#46; Este documento de consenso multidisciplinar actualiza la opini&#243;n de expertos y establece recomendaciones para el diagn&#243;stico y tratamiento de la infecci&#243;n tuberculosa latente en estos pacientes&#44; seg&#250;n los conocimientos actuales en terapias biol&#243;gicas&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Please cite this article as&#58; Rodr&#237;guez-Jim&#233;nez P&#44; Mir-Viladrich I&#44; Chicharro P&#44; Solano-L&#243;pez G&#44; L&#243;pez-Longo FJ&#44; Taxonera C&#44; et al&#46; Consenso multidisciplinar sobre prevenci&#243;n y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol&#243;gico&#46; Adaptaci&#243;n al paciente dermatol&#243;gico&#46; Actas Dermosifiliogr&#46; 2018&#59;109&#58;584&#8211;601&#46;</p>"
      ]
    ]
    "multimedia" => array:12 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1480
            "Ancho" => 2321
            "Tamanyo" => 174867
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Graphical representation of the extensive involvement of TNF in immune response to <span class="elsevierStyleItalic">M tuberculosis</span> infection&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 2665
            "Ancho" => 2167
            "Tamanyo" => 294523
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">In absence of anti-TNF&#44; cytotoxic effector memory T cells &#40;T<span class="elsevierStyleInf">EMRA</span>&#41; release granulomas with cytolytic enzymes &#40;perforin&#44; granulysin&#41; that destroy macrophages infected by <span class="elsevierStyleItalic">M tuberculosis</span> as well as intra- and extracellular bacilli&#46; In presence of anti-TNF&#44; transmembrane TNF of T<span class="elsevierStyleInf">EMRA</span> is bound to this antibody&#44; favoring lymphocyte apoptosis&#46; Depletion of cytotoxic T cells therefore prevents growth control and allows dissemination of <span class="elsevierStyleItalic">M tuberculosis</span>&#46;</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Source&#58; Adapted from Miller and Ernst&#46;<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">41</span></a></p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 891
            "Ancho" => 2088
            "Tamanyo" => 96337
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">BCG&#44; bacillus Calmette-Guerin&#59; IGRA&#44; interferon &#947; release assay&#46;</p> <p id="spar0035" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">a</span> Patients with CD4&#43; counts &#8805;&#160;500&#160;cells&#47;mL are considered immunocompetent&#46;</p> <p id="spar0040" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">b</span> In cases of severe immunosuppression &#40;CD4&#43; count &#60; 200 cells&#47;mL&#41;&#44; the probability of true infection should be assessed individually&#46;</p> <p id="spar0045" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">c</span> IGRA measurement can be repeated periodically &#40;depending on the individual risk in each patient&#41; without any booster effect&#46;</p> <p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Source&#58; Adapted from the Diagnostic and Treatment Guidelines for Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery &#40;SEPAR&#41;&#46;&#46;<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">75</span></a></p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figure 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1998
            "Ancho" => 2088
            "Tamanyo" => 209567
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Provisional algorithm for assessment of TB infection in candidates for anti-TNF treatment&#46;</p> <p id="spar0060" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">a</span> Appropriate treatment for TB is defined as &#8805;6 months of treatment with first-line drugs&#44; including &#8805;2 months of the combination of rifampicin&#44; isoniazid&#44; pyrazinamide and ethambutol&#46; Appropriate treatment for latent infection can be administration of &#8805;6 months of isoniazid&#44; 3 months of isoniazid and rifampicin&#44; or 4 months of rifampicin alone&#46;</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">b</span> The risk of latent infection is determined by weighting factors such as exposure to known contagious case&#44; age&#44; country of origin&#44; and work and social history of the individual&#44; including travel to endemic countries and repeated exposure to collectives at risk &#40;closed institutions&#44; homeless&#44; drug users&#41;&#46;</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">c</span> In those infected many years earlier&#44; TT can be negative and become positive in a second TT &#40;booster phenomenon&#41;&#46; With the availability of IGRAs&#44; it would seem more practical to use these as complementary tests rather than performing a second TT&#44; both in patients aged more than 60 years and in immunosuppressed patients due to different causes&#44; regardless of age&#46;</p> <p id="spar0075" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">d</span> There are no conclusive data to establish a safe period between the start of treatment for latent infection and the start of anti-TNF therapy&#46; Four weeks delay is considered usual practice and safe by most experts&#46;</p> <p id="spar0080" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">e</span>Active TB treatment should be completed before starting biological therapy&#46; See text for interpretation and extension of this algorithm&#46;</p> <p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Anti-TNF&#44; anti-tumor necrosis factor&#59; BCG&#44; bacillus Calmette-Guerin&#59; IGRA&#44; interferon &#947; release assay&#59; TB&#44; tuberculosis&#59; TT&#44; tuberculin test&#46;</p> <p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Source&#58; Adapted from Winthrop&#46;&#46;<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">120</span></a></p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="3" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Strength of Recommendation</th><th class="td" title="table-head  " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Recommendations by Scientific Quality</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Strong&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Recommendation supported&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Grade I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Recommendation based on at least 1 randomized&#44; controlled clinical trial with an appropriate design&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Recommendation supported&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Grade II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Recommendation based on at least 1 trial with an appropriate design but not randomized&#44; cohort studies&#44; multiple series&#44; or very evident results in uncontrolled trials&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Weak&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Recommendation cannot be either supported or rejected&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Grade III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Recommendation based on expert opinion in descriptive studies or in clinical experience&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838849.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Degree of Recommendation<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">18</span></a></p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#59; CHO&#44; Chinese hamster ovary&#59; TNF&#44; tumor necrosis factor&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Type of Biological Agent&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Indication Date of approval&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Infliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Chimeric IgG<span class="elsevierStyleInf">1</span> human-mouse IgG<span class="elsevierStyleInf">1</span> monoclonal anti-TNF antibody produced in murine hybridoma cells by recombinant DNA technology&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies&#46; August 1999&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Etanercept</td><td class="td" title="table-entry  " align="left" valign="top">Dimeric fusion protein of soluble extracellular domain of human TNF receptor 2 and Fc domain of human IgG1 produced by recombinant DNA techniques from a CHO cell culture&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies&#46; February 2000&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe chronic plaque psoriasis in children from 6 years of age whose disease is not controlled or who are intolerant to other systemic therapies&#46; February 2009&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Adalimumab</td><td class="td" title="table-entry  " align="left" valign="top">Recombinant human monoclonal anti-TNF antibody produced in CHO cells&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies&#46; September 2003&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe chronic plaque psoriasis in children from 4 years of age whose disease is not controlled or who are intolerant to other systemic therapies&#46; April 2015&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Patients at least 12 years of age with active moderate to severe hidrosadenitis suppurativa who do not respond appropriately to other conventional systemic treatments&#46; September 2015&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ustekinumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anti-p40 human monoclonal antibody &#40;IL12&#47;23 subunit&#41; that is produced in a mouse myeloma cell line using recombinant DNA technology&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Adults with moderate to severe plaque psoriasis who have not responded to or have contraindication to other systemic therapies&#46; January 2009&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Secukinumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fully human anti-IL-17&#44; IgG1&#47;&#954; monoclonal antibody&#44; produced in CHO cells&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Treatment of moderate to severe psoriasis vulgaris in adult candidates for systemic treatments&#46; March 2016&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ixekizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fully human anti-IL-17&#44; IgG1&#47;&#954; monoclonal antibody&#44; produced in CHO cells&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Treatment of moderate to severe psoriasis vulgaris in adult candidates for systemic treatments&#46; March 2017&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838845.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Type of Biological Agent&#44; Indication&#44; and Date of Approval&#46;</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; TC&#44; T-cell&#59; TNF&#44; tumor necrosis factor&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Classification</span><br>Effect&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drugs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Indications&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Theoretical Risk of TB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Lymphoblastic</span><br>Destruction of lymphoid tissue&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alkylating Agents Cyclophosphamide<br>Fludarabine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Chemotherapy<br>Systemic diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Antimetabolites</span><br>Inhibition of synthesis of purines and pyrimidines<br>Blockade of activated TC expansion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mycophenolate mofetil Azathioprine Methotrexate Leflunomide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Prevention of graft rejection<br>Systemic diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Antiproliferative</span><br>Agents control entry into S phase of the cell cycle by binding to the rapamycin receptor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sirolimus<br>Everolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Prevention of graft rejection<br>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Anticalcineurin</span><br>Agents inhibit TC activation signal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cyclosporin A<br>Tacrolimus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Prevention of graft rejection<br>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Corticosteroids</span><br>Agents inhibit all immunoinflammatory reactions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Prednisone<br>Methylprednisolone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Systemic diseases<br>Prevention of graft rejection<br>Oncology<br>Asthma&#44; hypersensitivity pneumonitis&#44; diffuse interstitial fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Anti-TNF</span><br>These inhibit TNF proinflammatory cytokines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Infliximab<br>Adalimumab<br>Etanercept<br>Golimumab Certolizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><br>Systemic diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#43;&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838846.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">Immunosuppressants That May Induce Tuberculosis&#46;</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0125" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; RA&#44; rheumatoid arthritis&#59; RR&#44; relative risk&#59; TNF&#44; tumor necrosis factor&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Incidence&#47;100&#160;000 and RR of Tuberculosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Spain<br>G&#243;mez-Reino et al&#46; &#40;2003<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">8</span></a>&#41;&#44; Carmona et al&#46; &#40;2005&#41;<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">13</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">USA<br>Wolfe et al&#46; &#40;2004&#41;<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sweden<br>Askling et al&#46; &#40;2005&#41;<a class="elsevierStyleCrossRef" href="#bib0885"><span class="elsevierStyleSup">57</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Korea<br>Seong et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">56</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In the general population &#40;RR&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#46;2 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4-14<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">67 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In RA &#40;RR&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">110 &#40;4&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">118&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">257 &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In RA with anti-TNF &#40;cumulative RR&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">20<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">24&#46;5 &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">36<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In RA with anti-TNF with recommendations &#40;RR&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">117 &#40;4&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#46;2 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Effectiveness&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Proven&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Proven&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Proven&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838847.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Incidence of hospitalization due to TB&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">Incidence and Relative Risk of Tuberculosis in Rheumatoid Arthritis Before and After Introduction of Anti-TNF Agents&#58; Impact of the Recommendations&#46;</p>"
        ]
      ]
      8 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0135" class="elsevierStyleSimplePara elsevierViewall">Abbreviation&#58; HIV&#44; human immunodeficiency virus&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Persons in recent contact with patients with TB disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Persons born or who live in countries with a high prevalence of TB or those who travel frequently to such countries for business&#44; family&#44; or humanitarian reasons&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Residents and workers in closed institutions such as prisons&#44; hostels for the destitute&#44; and social and health centers of any type&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Abuse of alcohol and other harmful substances&#44; while not forgetting that smokers develop TB more frequently than nonsmokers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Health workers&#44; in particular those who attend patients with active TB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Persons with radiologic lesions suggestive of old TB&#44; particularly if&#44; as in the case of positive tuberculin&#44; they have never received treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Very old and very young people&#44; immunosuppressive diseases&#44; and other comorbid conditions usually associated with increased risk of TB&#46; This group includes patients with HIV infection&#44; autoimmune diseases&#44; and post-transplantation period&#44; but also includes lung diseases &#40;silicosis&#41;&#44; chronic kidney disease&#44; gastrectomy&#44; diabetes&#44; and certain tumors such as those of the head and neck&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838851.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0130" class="elsevierStyleSimplePara elsevierViewall">Groups at High Risk of Conversion to Active Tuberculosis&#46;</p>"
        ]
      ]
      9 => array:8 [
        "identificador" => "tbl0030"
        "etiqueta" => "Table 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at6"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0145" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; Anti-TNF&#44; anti-tumor necrosis factor&#59; BCG&#44; bacillus Calmette-Guerin&#59; HIV&#44; human immunodeficiency virus&#59; IGRA&#44; interferon &#947; release assay&#59; QF&#44; Quantiferon&#59; TB&#44; tuberculosis&#59; TT&#44; tuberculin test&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Study&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Test&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">No&#46; of Patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Findings&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ponce de Le&#243;n et al&#46; &#40;2005&#41;<a class="elsevierStyleCrossRef" href="#bib0925"><span class="elsevierStyleSup">65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-In Tube</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">101&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">The percentage of TT positive patients was significantly lower in patients with inflammatory disease than in healthy controls and induration was also significantly less extensive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Pratt et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">70</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-Gold</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">101&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">98 patients &#40;4 of them with <span class="elsevierStyleItalic">QF-G</span> positive result&#41; received anti-TNF treatment with no documented cases of active TB after 30 months of follow-up&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Takahashi et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib1005"><span class="elsevierStyleSup">81</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-Gold</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Agreement between conventional study &#40;TT&#44; chest X-ray&#44; medical history&#41; and QF-G was moderate &#40;64&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cobanoglu et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib1020"><span class="elsevierStyleSup">84</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-In Tube</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">68&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Agreement between TT and <span class="elsevierStyleItalic">T-SPOT</span> was lower in healthy controls &#40;64&#37;&#41; and very low in patients with inflammatory diseases &#40;47&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sellam et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">85</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">T-SPOT&#46;TB</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Agreement between TT and <span class="elsevierStyleItalic">T-SPOT</span> in patients with documented TB infection &#40;radiographic abnormalities&#44; prior TB&#41; was moderate &#40;71&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Boccino et al&#46; &#40;2008&#41;<a class="elsevierStyleCrossRef" href="#bib0995"><span class="elsevierStyleSup">79</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-In Tube&#44; T-SPOT&#46;TB</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8&#47;15 patients with inflammatory diseases and risk factors for TB were positive for TT&#44; <span class="elsevierStyleItalic">QF</span>&#44; and <span class="elsevierStyleItalic">T-SPOT</span>&#46; The remaining 7 were negative for TT&#44; but positive for <span class="elsevierStyleItalic">QF</span> or <span class="elsevierStyleItalic">T-SPOT</span>&#46; 31&#47;35 patients with no risk factors negative for all tests&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Matulis et al&#46; &#40;2008&#41;<a class="elsevierStyleCrossRef" href="#bib1015"><span class="elsevierStyleSup">83</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-In Tube</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">142&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-IT</span> was more closely associated with having risk factors for TB&#46; The agreement between TT and <span class="elsevierStyleItalic">T-SPOT</span> was low &#40;64&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Vassilopoulos et al&#46; &#40;2008&#41;<a class="elsevierStyleCrossRef" href="#bib1010"><span class="elsevierStyleSup">82</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">T-SPOT&#46;TB</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">70&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">The agreement between TT and <span class="elsevierStyleItalic">T-SPOT</span> was moderate &#40;72&#37;&#41;&#46; In the multivariate analysis&#44; BCG vaccination was associated with a higher &#37; of TT&#43; and corticosteroids with a higher &#37; of <span class="elsevierStyleItalic">T-SPot</span>&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Santin et al&#46; &#40;2012&#41;<a class="elsevierStyleCrossRef" href="#bib0965"><span class="elsevierStyleSup">73</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">QF-In Tube&#44; T-SPOT&#46;TB</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><br>6514&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Meta-analysis &#40;38 studies&#41;&#44; IGRA&#58; limited capacity for ruling out TB in HIV&#43; patients&#46; Positive results are influenced by the disease load of the population studied&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838848.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0140" class="elsevierStyleSimplePara elsevierViewall">Results of Screening Tests for Latent Tuberculosis Infection in Patients with Systemic Inflammatory Diseases&#46;</p>"
        ]
      ]
      10 => array:8 [
        "identificador" => "tbl0035"
        "etiqueta" => "Table 7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at7"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Immunosuppressed</th></tr><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Without Taking Into Account BCG vaccination Status</th></tr><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TT &#60; 5mm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">TT &#8805; 5 mm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">IGRA negative &#40;IN&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No LTI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">LTI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">IGRA positive &#40;IP&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">LTI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">LTI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">IGRA indeterminate &#40;II&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#63;<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">LTI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838852.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Immunosuppressed patients with 1 or 2 positive screening tests should receive treatment for LTI with any of the recommended regimens&#46; Doubtful or indeterminate results should be repeated &#40;complement TT with IGRA or <span class="elsevierStyleItalic">T-SPOT&#46;TB</span>&#41;&#46;</p> <p class="elsevierStyleNotepara" id="npar0015">Abbreviations&#58; IGRA interferon &#947; release assay&#59; LTI latent tuberculosis infection&#59; TT tuberculin test&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0150" class="elsevierStyleSimplePara elsevierViewall">Interpretation of the Results of Screening in Immunosuppressed Patients&#46;</p>"
        ]
      ]
      11 => array:8 [
        "identificador" => "tbl0040"
        "etiqueta" => "Table 8"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at8"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0170" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; CT&#44; computed tomography&#59; IGRA&#44; interferon &#947; release assay&#59; IMID&#44; immune-mediated inflammatory disease&#59; INH&#44; isoniazid&#59; LTI&#44; latent tuberculosis infection&#59; TNF&#44; tumor necrosis factor&#44; RIF&#44; rifampicin&#59; TB&#44; tuberculosis&#59; TT&#44; tuberculin test&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">All candidates for biological therapies should be studied for diagnosis of LTI as these patients belong to one of the highest risk groups for developing TB&#46;<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">8&#44;9</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">The risk of these patients falling ill appears to be depend on the anti-TNF agent used&#58; infliximab and adalimumab are those with highest risk detected<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">8&#44;42</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">The diagnostic methods for LTI detection are based on<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">75</span></a>&#58;</td><td class="td" title="table-entry  " align="left" valign="top">Active search for TB history in the patient&#39;s medical record as well as contacts with active TB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Chest X-ray can detect possible old TB lesions&#46; In the case of doubt&#44; it is advised to complete the study with chest CT&#44; given that this technique is superior to chest X-ray for detection of early radiologic signs of active TB or old lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Simultaneous performance of IGRA and TT&#46; Any positive result in one of these tests is considered indicative of LTI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Patients diagnosed with IMIDs have a higher rate of false negatives with TT and IGRA&#46;<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">71&#44;72</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">There is no evidence that repeating TT &#40;booster effect&#41; increases the sensitivity of the test in patients with IMID but that it does reduce specificity&#44; and so currently&#44; with the use of IGRA&#44; the TT is not recommended<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">67</span></a></td><td class="td" title="table-entry  " align="left" valign="top">CIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">IGRA should be performed before TT&#44; due to the booster effect detected for IGRAs&#46;<a class="elsevierStyleCrossRefs" href="#bib1035"><span class="elsevierStyleSup">87&#44;88</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">The specificity and sensitivity of the 2 IGRA techniques for the diagnosis of LTI are similar in patients with IMID&#59; as the sensitivity of <span class="elsevierStyleItalic">T&#46;SPOT&#46;TB</span> is somewhat higher in patients treated with corticosteroids&#44; use of this test should be considered in these patients<a class="elsevierStyleCrossRefs" href="#bib0965"><span class="elsevierStyleSup">73&#44;74</span></a></td><td class="td" title="table-entry  " align="left" valign="top">BIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Indeterminate results should always be confirmed with a second measurement that&#44; in most cases&#44; is negative<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">71&#44;72</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Negativity in the TT and IGRA does not rule out LTI&#46;<a class="elsevierStyleCrossRefs" href="#bib0930"><span class="elsevierStyleSup">66&#44;66&#44;70&#44;82</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Preventive treatment is recommended in all candidates for therapy who presented with suspicion of LTI&#44; after excluding active TB&#44; in any of the diagnostic tests<a class="elsevierStyleCrossRefs" href="#bib1060"><span class="elsevierStyleSup">92&#44;93&#44;96&#44;115&#44;116</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Monitoring of treatment should be done monthly&#46; In the case of INH liver toxicity&#44; a 4-month RIF regimen is recommended<a class="elsevierStyleCrossRef" href="#bib1165"><span class="elsevierStyleSup">113</span></a><br></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">A period of 4 weeks of treatment for LTI is considered safe &#40;by most experts&#41; for starting treatment with anti-TNF<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">61</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">The study and screening for LTI&#44; after onset of anti-TNF treatment and during maintenance&#44; as a diagnostic strategy in initial false negatives is not supported by evidence currently available&#46; It is recommended to repeat the screening study if there are changes in clinical symptoms or potential exposure to <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> due to travel to regions where infection is endemic<a class="elsevierStyleCrossRefs" href="#bib1040"><span class="elsevierStyleSup">88&#8211;91</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">If the patient is diagnosed with active tuberculosis disease&#44; anti-TNF treatment should be suspended&#59; it is recommended to delay reinitiating until the entire TB treatment cycle has been completed&#46; There is no evidence that the duration of treatment for TB disease should be modified in this context<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">61</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Patients who have correctly completed treatment for TB do not appear to be at a higher risk of relapse when anti-TNF treatment is initiated<a class="elsevierStyleCrossRefs" href="#bib1070"><span class="elsevierStyleSup">94&#44;95</span></a></td><td class="td" title="table-entry  " align="left" valign="top">AIII&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838850.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0165" class="elsevierStyleSimplePara elsevierViewall">Final Recommendations with Degree of Evidence&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:120 [
            0 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Tuberculosis global report 2017&#46; World Health Organization &#91;accessed Sep 2017&#93;&#46; Available from&#58; <a id="intr0005" class="elsevierStyleInterRef" href="http://www.who.int/tb">www&#46;who&#46;int&#47;tb</a>"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy&#58; Report of a case series with 144 patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1468-3083.2010.03836.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2011"
                        "volumen" => "25"
                        "paginaInicial" => "730"
                        "paginaFinal" => "733"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "What can we learn by following the development of tuberculosis from one generation to another&#63; 1930"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Tuberc Lung Dis"
                        "fecha" => "2002"
                        "volumen" => "6"
                        "paginaInicial" => "562"
                        "paginaFinal" => "568"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A method for estimating the prevalence of tuberculosis infection"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Epidemiol&#46;"
                        "fecha" => "1975"
                        "volumen" => "101"
                        "paginaInicial" => "311"
                        "paginaFinal" => "322"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Infliximab approval process in Crohn&#39;s disease&#46; Deparment of Health and Human Services&#46; Public Health Service&#46; Food and Drug Administration&#59; August 24&#44; 1998&#46;"
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Updated consensus statement on biological agents for the treatment of rheumatic diseases&#44; 2009"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2009.123885"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2010"
                        "volumen" => "69"
                        "numero" => "Suppl I"
                        "paginaInicial" => "i2"
                        "paginaFinal" => "i29"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tuberculosis associated with infliximab&#44; a tumor necrosis factor-alpha neutralizing agent"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa011110"
                      "Revista" => array:7 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2001"
                        "volumen" => "345"
                        "paginaInicial" => "1098"
                        "paginaFinal" => "1104"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk&#58; A multicenter active-surveillance report"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.11137"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2003"
                        "volumen" => "48"
                        "paginaInicial" => "2122"
                        "paginaFinal" => "2127"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Latent tuberculosis infection and active tuberculosis in patients with psoriasis&#58; A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain&#46; BIOBADADERM registry"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.12011"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2012"
                        "volumen" => "27"
                        "paginaInicial" => "1366"
                        "paginaFinal" => "1374"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab CB Spanish Working Group on Crohn Disease and Ulcerative Colitis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterol Hepatol"
                        "fecha" => "2003"
                        "volumen" => "26"
                        "paginaInicial" => "29"
                        "paginaFinal" => "33"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-tumour necrosis factor agents and tuberculosis risk&#58; Mechanisms of action and clinical management"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Infect Dis"
                        "fecha" => "2003"
                        "volumen" => "3"
                        "paginaInicial" => "148"
                        "paginaFinal" => "155"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.autrev.2015.01.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Autoimmun Rev&#46;"
                        "fecha" => "2015"
                        "volumen" => "14"
                        "paginaInicial" => "503"
                        "paginaFinal" => "509"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21043"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2005"
                        "volumen" => "52"
                        "paginaInicial" => "1766"
                        "paginaFinal" => "1772"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Crohn Colitis&#46;"
                        "fecha" => "2013 Apr 1"
                        "volumen" => "7"
                        "paginaInicial" => "208"
                        "paginaFinal" => "212"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Glucocorticoid use&#44; other associated factors&#44; and the risk of tuberculosis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21705"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum&#46;"
                        "fecha" => "2006"
                        "volumen" => "55"
                        "paginaInicial" => "19"
                        "paginaFinal" => "26"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consensus document on prevention and treatment of tuberculosis in patients for biological treatment"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.arbres.2015.04.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Bronconeumol&#46;"
                        "fecha" => "2016"
                        "volumen" => "52"
                        "paginaInicial" => "36"
                        "paginaFinal" => "45"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Purpose of quality standards for infectious diseases"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Infect Dis&#46;"
                        "fecha" => "1994"
                        "volumen" => "18"
                        "paginaInicial" => "421"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "e1-20"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Documento de consenso sobre diagn&#243;stico&#44; tratamiento y prevenci&#243;n de la tuberculosis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eimc.2010.02.006"
                      "Revista" => array:5 [
                        "tituloSerie" => "Enferm Infecc Microbiol Clin&#46;"
                        "fecha" => "2010"
                        "volumen" => "28"
                        "paginaInicial" => "297"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency&#46; Ficha t&#233;cnica de Remicade &#40;infliximab&#41; &#91;accessed Sep 2017&#93;&#46; Available from&#58; <a id="intr0010" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;docs&#47;es&#95;ES&#47;document&#95;library&#47;EPAR&#95;-&#95;Product&#95;Information&#47;human&#47;000240&#47;WC500050888&#46;pdf</a>"
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency&#46; Ficha t&#233;cnica de Enbrel &#40;etanercept&#41; &#91;accessed Sep 2017&#93;&#46; Available from&#58; <a id="intr0015" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;docs&#47;es&#95;ES&#47;document&#95;library&#47;EPAR&#95;-&#95;Product&#95;Information&#47;human&#47;000262&#47;WC500027361&#46;pdf</a>"
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0705"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency&#46; Ficha t&#233;cnica de Humira &#40;adalimumab&#41; &#91;accessed Sep 2017&#93;&#46; Available from&#58; <a id="intr0020" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;docs&#47;es&#95;ES&#47;document&#95;library&#47;EPAR&#95;-&#95;Product&#95;Information&#47;human&#47;000481&#47;WC500050870&#46;pdf</a>"
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0710"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency&#46; Ficha t&#233;cnica de Stelara &#40;ustekinumab&#41; &#91;accessed Sep 2017&#93;&#46; Available from&#58; <a id="intr0025" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;docs&#47;es&#95;ES&#47;document&#95;library&#47;EPAR&#95;-&#95;Product&#95;Information&#47;human&#47;000958&#47;WC500058513&#46;pdf</a>"
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0715"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency&#46; Ficha t&#233;cnica de Cosentyx &#40;secukinumab&#41; &#91;accessed Sep 2017&#93;&#46; Available from&#58; <a id="intr0030" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003729/WC500183129.pdf">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;docs&#47;es&#95;ES&#47;document&#95;library&#47;EPAR&#95;-&#95;Product&#95;Information&#47;human&#47;003729&#47;WC500183129&#46;pdf</a>"
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0720"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Medicines Agency&#46; Ficha t&#233;cnica de Taltz &#40;ixekizumab&#41; &#91;accessed Sep 2017&#93;&#46; Available from&#58; <a id="intr0035" class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;docs&#47;es&#95;ES&#47;document&#95;library&#47;EPAR&#95;-&#95;Product&#95;Information&#47;human&#47;003943&#47;WC500205804&#46;pdf</a>"
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0725"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Etanercept for the treatment of psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Expert Rev Dermatol"
                        "fecha" => "2013"
                        "volumen" => "8"
                        "paginaInicial" => "357"
                        "paginaFinal" => "372"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0730"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The use of infliximab in dermatology"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1610-0387.2007.06319.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dtsch Dermatol Ges&#46;"
                        "fecha" => "2007"
                        "volumen" => "5"
                        "paginaInicial" => "655"
                        "paginaFinal" => "660"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0735"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The future of biological therapies"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.sder.2010.02.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Cutan Med Surg&#46;"
                        "fecha" => "2010"
                        "volumen" => "29"
                        "paginaInicial" => "63"
                        "paginaFinal" => "66"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0740"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ustekinumab improves psoriasis without altering T cell cytokine production&#44; differentiation&#44; and T cell receptor repertoire diversity"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0051819"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLoS One&#46;"
                        "fecha" => "2012"
                        "volumen" => "7"
                        "paginaInicial" => "e51819"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0745"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "British Association of Dermatologists&#8217; guidelines for biologic interventions for psoriasis 2009"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2009.09505.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2009"
                        "volumen" => "161"
                        "paginaInicial" => "987"
                        "paginaFinal" => "1019"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0750"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "e4"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab long-term safety experience&#58; A pooled analysis of 10 phase ii and iii clinical studies in patients with moderate to severe plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2016.03.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "75"
                        "paginaInicial" => "83"
                        "paginaFinal" => "98"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0755"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of ixekizumab therapy&#58; Integrated analysis of 3 double-blind&#44; controlled trials UNCOVER-1&#44; UNCOVER-2&#44; UNCOVER-3"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "J Invest Dermatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "136"
                        "paginaInicial" => "S170"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0760"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adalimumab for the treatment of moderate to severe hidradenitis suppurativa"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-157-12-201212180-00004"
                      "Revista" => array:5 [
                        "tituloSerie" => "Ann Intern Med&#46;"
                        "fecha" => "2012"
                        "volumen" => "157"
                        "paginaInicial" => "846"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0765"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Brodalumab&#44; an anti&#8211;interleukin-17&#8211;receptor antibody for Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "N Eng J Med&#46;"
                        "fecha" => "2012"
                        "volumen" => "366"
                        "paginaInicial" => "1181"
                        "paginaFinal" => "1189"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0770"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "N Eng J Med&#46;"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "136"
                        "paginaFinal" => "144"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0775"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tildrakizumab &#40;MK-3222&#41;&#44; an anti-interleukin-23p19 monoclonal antibody&#44; improves psoriasis in a phase IIb randomized placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.13932"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "173"
                        "paginaInicial" => "930"
                        "paginaFinal" => "939"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0780"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "e12507"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2017"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0785"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized phase 2<span class="elsevierStyleHsp" style=""></span>a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.12266"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2013"
                        "volumen" => "169"
                        "paginaInicial" => "137"
                        "paginaFinal" => "145"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0790"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tuberculose&#44; agents anti-TNF et autres immunosuppresseurs&#58; &#201;volution des strat&#233;gies de pr&#233;vention"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Mal Respir"
                        "fecha" => "2008"
                        "volumen" => "25"
                        "paginaInicial" => "1237"
                        "paginaFinal" => "1249"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0795"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "abstr 356"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Tuberculosis and etanercept&#46; Proceedings of American College of Rheumatology Conference"
                        "fecha" => "2002 October"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0800"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Vaccine Immunol&#46;"
                        "fecha" => "2008"
                        "volumen" => "155"
                        "paginaInicial" => "506"
                        "paginaFinal" => "512"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0805"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-TNF immunotherapy and tuberculosis reactivation&#58; Another mechanism revealed"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Invest"
                        "fecha" => "2009"
                        "volumen" => "119"
                        "paginaInicial" => "1079"
                        "paginaFinal" => "1082"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0810"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy&#58; Results from the British Society of Rheumatology Biologics Register &#40;BSRBR&#41;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2009.118935"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2010"
                        "volumen" => "69"
                        "paginaInicial" => "522"
                        "paginaFinal" => "528"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0815"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2012.11162.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2012"
                        "volumen" => "168"
                        "paginaInicial" => "444"
                        "paginaFinal" => "446"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0820"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archdermatol.2012.2958"
                      "Revista" => array:5 [
                        "tituloSerie" => "Arch Dermatol&#46;"
                        "fecha" => "2012"
                        "volumen" => "148"
                        "paginaInicial" => "1332"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0825"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "FRI0025 no reactivation of dormant <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> in human in vitro granuloma model after anti-IL-17A treatment&#44; in contrast to anti-TNF &#945; treatment"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2016"
                        "volumen" => "75"
                         …3
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0830"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of anti-IL-17A&#44; IL-17F and TNF-&#945; antibodies on host resistance to acute Mycobacterium tuberculosis infection in mice"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0835"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab treatment shows no evidence for reactivation of previous or latent TB infection in subjects with psoriasis&#58; A pooled phase 3 safety analysis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0840"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-TNF immunotherapy reduces CD8 T cell-mediated antimicrobial activity against <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> in humans"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1172/JCI38482"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0845"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An antimicrobial activity of cytolytic T cells mediated by granulysin"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0850"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Differential effects of cytolytic T cell subsets on intracellular infection"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0855"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "XCLI &#40;lymphotactin&#41; chemokine produced by activated CD8 T cells during the chronic stage of infeciton with <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1189/jlb.0607426"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0860"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Control of latent <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> infection is dependent on CD8 T cells"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0865"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "<span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> growth control by lung macrophages and CD8 cells from patient contacts"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200503-411OC"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0870"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tumor necrosis factors signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.immuni.2008.06.011"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0875"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.20009"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0880"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Incidence of tuberculosis in Korean patients with rheumatoid arthritis &#40;RA&#41;&#58; Effects of RA itself and of tumor necrosis factor blockers"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0885"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21137"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0890"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "TB in patients receiving anti-TNF agents despite chemoprophylaxis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0895"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "TB in the cytokine era&#58; What rheumatologist need to know"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.11134"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0900"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases&#58; Diagnostic and therapeutic strategies"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0b013e3283025ec2"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0905"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reinitiation of biologics after the development of tuberculosis under anti-TNF therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0910"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor &#40;TNF&#41;-&#945; antagonist therapy&#58; Safe re-initiation of TNF-&#945; blockers after appropriate anti-tuberculous treatment"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1469-0691.2007.01891.x"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0915"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Is it safe to readminister tumor necrosis factor &#945; antagonists following tuberculosis flare&#63;"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.23210"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0920"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Screening for latent tuberculosis in the patient with moderate to severe psoriasis who is a candidate for systemic and&#47;or biologic therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2015.10.004"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0925"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Attenuated response to purified protein derivative in patients with rheumatoid arthritis&#58; Study in a population with a high prevalence of tuberculosis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2004.029041"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0930"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of an interferon-&#947; assay with tuberculin skin testing for detection of tuberculosis &#40;TB&#41; infection in patients with rheumatoid arthritis in a TB-endemic population"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0935"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The tuberculin skin test"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0940"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Cellestis&#46; Quantiferon-TB Gold&#46; 2009 &#91;accessed 20 oct 2009&#93;&#46; Available from&#58; <a id="intr0040" class="elsevierStyleInterRef" href="http://www.cellestis.com/">http&#58;&#47;&#47;www&#46;cellestis&#46;com&#47;</a>"
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0945"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "OxfordImmunotec&#46; T&#46; Spot-TB&#46; 2009 &#91;accessed 20 oct 2009&#93;&#46; Available from&#58; <a id="intr0045" class="elsevierStyleInterRef" href="http://www.oxfordimmunotec.com/">http&#58;&#47;&#47;www&#46;oxfordimmunotec&#46;com&#47;</a>"
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0950"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of two commercially available gamma-interferon blood tests for immunodiagnosis of tuberculosis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1128/CVI.00364-07"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0955"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Updated guidelines for using interferon g release assays to detect <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> infection&#8212;United States&#44; 2010"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0960"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Centre for Disease Prevention and Control &#40;ECDC&#41;&#46; Use of interferon-gamma release assays in support of TB diagnosis &#91;accessed 7 jul 2013&#93;&#46; Available from&#58; <a id="intr0050" class="elsevierStyleInterRef" href="http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf">http&#58;&#47;&#47;ecdc&#46;europa&#46;eu&#47;en&#47;publications&#47;Publications&#47;1103&#95;GUI&#95;IGRA&#46;pdf</a>"
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0965"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "e32482"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interferon-&#947; release assay for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults&#58; A systematic review and metaanalysis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0125979"
                      "Revista" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib0970"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Executive summary of the guidelines for the use of interferon-gamma release assays in the diagnosis of tuberculosis infection"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.arbres.2016.02.020"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib0975"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Normativa SEPAR&#46; Diagn&#243;stico y tratamiento de la tuberculosis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib0980"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of Quantiferon-TB-Gold in Tube&#174; test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eimc.2012.06.014"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib0985"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of an <span class="elsevierStyleItalic">in vitro</span> tuberculosis interferon-&#947; assay with delayed-type hypersensitivity testing for detection of latent <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span>&#58; A pilot study in rheumatoid arthritis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib0990"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Agreement between Quantiferon-TB Gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3899/jrheum.090268"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib0995"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Performance of two commercial blood IFN-gamma release assays for the detection of <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> infection in patient candidates for anti-TNF-alpha treatment"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10096-008-0519-1"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib1000"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of Quantiferon TB Gold test as a part of a screening progrmme in patients with RA under consideration for treatment with antiTNF-alpha agents&#58; The Newcastle &#40;UK&#41; experience"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/kem064"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib1005"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00296-007-0361-2"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib1010"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Usefulness of enzyme-linked immunospot assay &#40;Elispot&#41; compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib1015"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> antigen specific IFN-gamma assay"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2007.070789"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib1020"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib1025"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2007.069799"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib1030"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "IFN-gamma release assay to diagnose TB infection in the immunocompromised individual"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/ers.09.20"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib1035"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.200811-1704OC"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib1040"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-3083.2008.02103.x"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib1045"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-a inhibitors"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.12037"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib1050"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFa inhibitors&#58; The utility of IFNg assay"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2011-200489"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib1055"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor-alpha antagonists"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/ar3882"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib1060"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Targeted tuberculin testing and treatment of latent tuberculosis infection&#46; Am J Respir Crit Care Med&#46; 2000&#59;161&#58;S221&#46;"
                ]
              ]
            ]
            92 => array:3 [
              "identificador" => "bib1065"
              "etiqueta" => "93"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical practice"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMcp1005750"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            93 => array:3 [
              "identificador" => "bib1070"
              "etiqueta" => "94"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Isoniazid prophylaxis among Alaskan Eskimos&#58; A final report of the bethel isoniazid studies"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/arrd.1979.119.5.827"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            94 => array:3 [
              "identificador" => "bib1075"
              "etiqueta" => "95"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Short-course therapy with rifampin plus isoniazid&#44; compared with standard therapy with isoniazid&#44; for latent tuberculosis infection&#58; A meta-analysis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1086/427802"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            95 => array:3 [
              "identificador" => "bib1080"
              "etiqueta" => "96"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update&#58; Adverse event data and revised American Thoracic Society&#47;CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-- United States&#44; 2003"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            96 => array:3 [
              "identificador" => "bib1085"
              "etiqueta" => "97"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Efficacy of various durations of isoniazid preventive therapy for tuberculosis&#58; Five years of follow-up in the IUAT trial&#46; International Union Against Tuberculosis Committee on Prophylaxis&#46; Bull World Health Organ&#46; 1982&#59;60&#58;555-564&#46;"
                ]
              ]
            ]
            97 => array:3 [
              "identificador" => "bib1090"
              "etiqueta" => "98"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults&#63;"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            98 => array:3 [
              "identificador" => "bib1095"
              "etiqueta" => "99"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Isoniazid therapy for latent tuberculosis in psoriasis patients receiving biological agents&#58; Is it safe and efficacious&#63;"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.12127"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            99 => array:3 [
              "identificador" => "bib1100"
              "etiqueta" => "100"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Peripheral neuritis in tuberculous patients treated with isoniazid"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            100 => array:3 [
              "identificador" => "bib1105"
              "etiqueta" => "101"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "62"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of a shortage of first-line antituberculosis medication on tuberculosis control&#44; United States&#44; 2012-2013"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            101 => array:3 [
              "identificador" => "bib1110"
              "etiqueta" => "102"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rifampin preventive therapy for tuberculosis infection&#58; Experience with 157 adolescents"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/ajrccm.155.5.9154885"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            102 => array:3 [
              "identificador" => "bib1115"
              "etiqueta" => "103"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection&#58; A randomized trial"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            103 => array:3 [
              "identificador" => "bib1120"
              "etiqueta" => "104"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.130.6.1712"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            104 => array:3 [
              "identificador" => "bib1125"
              "etiqueta" => "105"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on rifampin&#44; rifabutin&#44; and rifapentine drug interactions"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1185/03007995.2013.795141"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            105 => array:3 [
              "identificador" => "bib1130"
              "etiqueta" => "106"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interactions between antiretroviral agents and those used to treat tuberculosis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/COH.0b013e3282fbaad0"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            106 => array:3 [
              "identificador" => "bib1135"
              "etiqueta" => "107"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5588/ijtld.12.0510"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            107 => array:3 [
              "identificador" => "bib1140"
              "etiqueta" => "108"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in Southern India&#58; A trial-based analysis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0036001"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            108 => array:3 [
              "identificador" => "bib1145"
              "etiqueta" => "109"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of latent tuberculosis infection in HIV&#58; Shorter or longer&#63;"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11904-012-0120-1"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            109 => array:3 [
              "identificador" => "bib1150"
              "etiqueta" => "110"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Recommendations for therapy&#44; chemoprevention and chemoprophylaxis of tuberculosis in adults and children&#46; German Central Committee against Tuberculosis &#40;DZK&#41;&#44; German Respiratory Society &#40;DGP&#41;"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1055/s-0031-1291619"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            110 => array:3 [
              "identificador" => "bib1155"
              "etiqueta" => "111"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Strategies for treating latent multiple-drug resistant tuberculosis&#58; A decision analysis"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0030194"
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            111 => array:3 [
              "identificador" => "bib1160"
              "etiqueta" => "112"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on tuberculosis&#58; TB in the early 21st century"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09059180.00000511"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            112 => array:3 [
              "identificador" => "bib1165"
              "etiqueta" => "113"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of latent tuberculosis infection in HIV infected persons"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            113 => array:3 [
              "identificador" => "bib1170"
              "etiqueta" => "114"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#91;Tuberculosis in HIV&#47;AIDS patients&#93; &#91;art&#237;culo en japon&#233;s&#93;"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            114 => array:3 [
              "identificador" => "bib1175"
              "etiqueta" => "115"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-&#945; agents"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5114/aoms.2013.33352"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            115 => array:3 [
              "identificador" => "bib1180"
              "etiqueta" => "116"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Danish Society for Gastroenterology Guidelines for screening&#44; prophylaxis and critical information prior to initiating anti-TNF-alpha treatment"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            116 => array:3 [
              "identificador" => "bib1185"
              "etiqueta" => "117"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-&#947; release assay in patients considered for anti-tumor necrosis factor-&#945; therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.diagmicrobio.2010.12.020"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            117 => array:3 [
              "identificador" => "bib1190"
              "etiqueta" => "118"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis&#58; Systematic review"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            118 => array:3 [
              "identificador" => "bib1195"
              "etiqueta" => "119"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "TNF-alpha blockade and tuberculosis&#58; Better look before you leap"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            119 => array:3 [
              "identificador" => "bib1200"
              "etiqueta" => "120"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "You can&#8217;t always get what you want&#44; but if you try sometimes &#40;with two tests &#8212;TST and IGRA&#8212;for tuberculosis&#41; you get what you need"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2012-201979"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018302324/v1_201809020417/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "23902"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Special Article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000007/v1_201809020417/S1578219018302324/v1_201809020417/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302324?idApp=UINPBA000044"
]

Información del artículo

ISSN: 15782190
Idioma original: Inglés

DOI:10.1016/j.adengl.2018.06.020

Datos actualizados diariamente

año/Mes	Html	Pdf	Total

2024 Noviembre	18	9	27
2024 Octubre	138	73	211
2024 Septiembre	196	38	234
2024 Agosto	143	72	215
2024 Julio	144	32	176
2024 Junio	157	47	204
2024 Mayo	139	54	193
2024 Abril	126	38	164
2024 Marzo	126	40	166
2024 Febrero	110	43	153
2024 Enero	83	36	119
2023 Diciembre	109	31	140
2023 Noviembre	157	36	193
2023 Octubre	125	42	167
2023 Septiembre	117	35	152
2023 Agosto	93	31	124
2023 Julio	137	61	198
2023 Junio	122	40	162
2023 Mayo	136	36	172
2023 Abril	139	32	171
2023 Marzo	104	29	133
2023 Febrero	123	36	159
2023 Enero	84	34	118
2022 Diciembre	79	51	130
2022 Noviembre	62	23	85
2022 Octubre	42	24	66
2022 Septiembre	31	65	96
2022 Agosto	32	36	68
2022 Julio	23	41	64
2022 Junio	30	42	72
2022 Mayo	97	52	149
2022 Abril	127	60	187
2022 Marzo	129	65	194
2022 Febrero	111	38	149
2022 Enero	86	64	150
2021 Diciembre	93	55	148
2021 Noviembre	96	75	171
2021 Octubre	89	52	141
2021 Septiembre	79	53	132
2021 Agosto	85	60	145
2021 Julio	69	50	119
2021 Junio	70	48	118
2021 Mayo	102	65	167
2021 Abril	166	86	252
2021 Marzo	89	74	163
2021 Febrero	77	58	135
2021 Enero	59	37	96
2020 Diciembre	62	45	107
2020 Noviembre	62	45	107
2020 Octubre	56	43	99
2020 Septiembre	57	39	96
2020 Agosto	40	35	75
2020 Julio	35	31	66
2020 Junio	55	60	115
2020 Mayo	25	28	53
2020 Abril	14	21	35
2020 Marzo	23	13	36
2020 Febrero	1	0	1
2018 Octubre	1	2	3
2018 Septiembre	0	1	1
2018 Agosto	0	2	2

Mostrar todo

Indexada en:

Síguenos:

Estadísticas

Indexada en:

Síguenos:

Estadísticas

Suscríbase a la newsletter